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ABSTRACT
With the increasing prevalence of antimicrobial resistance, the escalation of
opportunistic/pathogenic infections is a looming global crisis. To avoid the pitfalls of
conventional antibiotics, this dissertation focuses on developing macromolecular
solutions to develop novel antimicrobial materials based on essential oils (thymol,
carvacrol, and aldehydes). It is well established that essential oil derivatives exhibit high
potency towards a wide range of pathogenic microbes. The rapid photopolymerization
kinetics, limited by-products, and homogeneous network formation afforded by thiol-ene
photopolymerization are utilized to either encapsulate essential oil derivatives or convert
them into monomers which can subsequently be incorporated into new antimicrobial
materials with new structure-function relationships.
The first chapter of this dissertation outlines the need for alternatives to traditional
antibiotics and the motivation for developing essential oil-based therapies. In the second
chapter, the utilization of thiol-ene chemistry in the design of drug delivery and
encapsulation are reviewed. The third chapter of this dissertation focus on the
development of one-pot/solvent-free thiol-ene miniemulsion technique to synthesize
thymol/carvacrol-loaded nanoparticles with high loading capacity (≈50% w/w), excellent
encapsulation efficiencies (>95%), and potent antimicrobial activity. In the following
chapters, new pro-antimicrobial networks via degradable acetals (PANDAs) were
fabricated as a new paradigm for the sequestration and triggered release of volatile,
antimicrobial aldehydes. PANDAs are crosslinked networks in which every crosslink
junction contains a degradable acetal linkage. When PANDAs are exposed to neutral to
acidic conditions (pH < 8), the PANDAs undergo surface erosion and exhibit sustained
ii

aldehyde release from days to months. Chapter IV details the fabrication of PANDAs
with a synthetic aldehyde, chlorobenzaldehyde, while chapter V emphases on the use of
the plant-derived, p-anisaldehyde (an extract from star anise). In both chapters, the
synthesis of PANDAs, thermal/mechanical properties, aldehyde release kinetics, as well
as antimicrobial efficacy and cytotoxicity were elucidated.
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CHAPTER I – ESSENTIAL OILS AS ANTIMICROBIAL AGENTS: CHALLENGES
AND DESIGN STRATEGIES
1.1 Antimicrobial Resistance
With 700,000 annual deaths globally, antimicrobial resistance (AMR) – attributed
in part to overuse and misuse of antibiotics in medicine and agriculture – is a global crisis
that seriously threatens the sustainability of public health.1 Without significant steps
toward solving AMR, a recent review predicts 10 million deaths annually attributed to
AMR in 2050.1 AMR occurs when pathogenic microbes are able to survive and grow
after exposure to antibiotics that would normally kill/inhibit their growth.2 Infections
caused by AMR strains are deadly, difficult to treat with common antibiotics, often
require toxic/costly treatments, and create broader infection control problems (spreading
infections globally).3 Compounding the issue of AMR, over 23.5 million Americans are
more susceptible to common infections due to weakened immune systems (i.e. elderly or
patients with rheumatoid arthritis, HIV, organ transplants, etc.).4 To mitigate the rapid
rise of AMR and protect immunocompromised individuals, new antibiotics and new
approaches to control the spread and evolution of AMR pathogens are required.
Additionally, a conscious effort to reduce use of antibiotics in medicine and agriculture is
critical. The continuous emergence of resistant pathogens, scarcity of new antimicrobial
drug scaffolds in the pharmaceutical discovery pipeline, and public demand for
antibiotic-free food production have led to growing interest in natural, plant-derived
extracts, or essential oils, as alternatives and/or supplements to synthetic antibiotics.
1.2 Essential oils as antimicrobials
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Essential oils (EOs) are complex mixtures of bioactive phytochemicals, including
aldehydes, terpenes, terpenoids, and phenolics, that are known to exhibit broad spectrum
antimicrobial activity and represent an attractive alternative to conventional antibiotics.5-6
Most EO constituents are selective towards pathogenic bacteria without promoting
resistance and the Food and Drug Administration has classified many EOs and individual
constituents of EOs with Generally Regarded as Safe (GRAS) status.3, 7-8 EOs have
recently found applications as food preservatives9, packaging additives7, textile
fragrances10, pesticides11, and therapeutic applications12-13. Additionally, EOs have been
successfully used as an exceptionally potent treatment against biofilm forming bacteria
Pseudomonas aeruginosa and Staphylococcus aureus.14 EOs as an antimicrobial
treatment exhibit fewer adverse effects, have higher patient tolerance, and are relatively
inexpensive compared to traditional antibiotics.3
Studies have shown that EOs eradicate microbial populations by targeting innerand-outer membranes, membrane proteins, and intracellular targets.15 It is important to
note that determining the mode of action for each EO constituent is not trivial. EO
constituents have shown to affect multiple-connected pathways without specified
targets.15 To complicate matters further, different species of bacteria may exhibit
different responses to each EO constituent. For a review of EO mechanisms of action and
potential targets, we encourage reading comprehensive reviews by Hyldgaard7, Burt15,
and Nazzaro16.
1.3 Essential oil challenges
Despite historical interest in EOs, significant challenges for practical
implementation of phytochemicals as antimicrobial agents stem from the hydrophobicity
2

(poor water solubility), volatility, and instability of many EO constituents.17 Poor water
solubility particularly limits the bioavailability of these compounds and significantly
lowers biological and antimicrobial activity, whereas volatility is problematic for
achieving sustained release and controlled delivery. Many strategies have been reported
to sequester or encapsulate EOs within films or colloidal systems; however, these
strategies often suffer deficiencies such as low loading, poor encapsulation efficiencies,
necessity of organic processing solvents, and uncontrolled burst release profiles.18 19
Encapsulation and controlled/sustained release of EO constituents could help to
overcome these issues and lead to the wider use of these plant-derived antimicrobials in
the food industry and agriculture.
1.4 Encapsulation and release of phytochemicals via the “polyactive” approach.
Many approaches have been reported to encapsulate hydrophobic EO constituents
within polymer systems in attempt to address the challenges (poor solubility, volatility,
oxidative instability, low bioavailability, uncontrolled delivery) associated with
implementation of EOs as alternative antimicrobials.20-21 Previous studies have shown
that encapsulating EOs improves both their aqueous stability and increases their
antimicrobial activity.22 23 These approaches however, predominately focused on physical
mixtures and non-covalent interactions resulting in low loading, poor encapsulation
efficiency, and burst release profiles. Recent work in the area of polyactives offers a
viable solution to these challenges. “Polyactives” refer to polymeric pro-drugs that
undergo partial or complete degradation to release active therapeutic agents (e.g., antiinflammatory, antioxidant, antibiotic).24 Phytochemical-based polyactives, reported by
Lee et al., released vanillin from a linear polyoxalate backbone for antioxidant
3

properties.25-26 Similarly, Uhrich et al. demonstrated antioxidant and antimicrobial
activities via the release of EDTA/phenolics (carvacrol, thymol, and eugenol)27 and
pinosylvin28 from linear poly(anhydride esters). These few examples illustrate the ability
to effectively sequester phytochemicals as biodegradable polyactives with high loading
(50 – 100 wt %) and sustained, tunable release profiles.
1.5 Our approach
The work highlighted in this dissertation focuses on the encapsulation,
sequestration, and release of antimicrobial EO derivatives from thiol-ene networks. The
second chapter of this dissertation provides a detailed review of how thiol-ene chemistry
has been harnessed to design novel encapsulation/delivery platforms of model
hydrophobic compounds. The third chapter demonstrates the direct encapsulation of
phenolic phytochemicals (carvacrol and thymol) within thiol-ene nanoparticles for
sustained delivery. Chapters 4 and 5 present a new paradigm for sequestration and release
of EOs within phytochemical-derived polymer systems – an approach that draws
inspiration from well-established “pro-drug” and “pro-fragrance” strategies employed
successfully in pharma and cosmetic industries.29-30 We focus on the design of
poly(thioether acetal) polymer networks in which aldehydes (e.g., anisaldehyde and
chlorobenzaldehyde) are covalently incorporated into the polymer network via an acetal
linkage – as an integral part of the polymer backbone. These materials serve as proantimicrobial networks (PANs) that release active antimicrobial aldehydes upon exposure
to conditions conducive to acetal degradation (e.g., change in humidity/pH). The PAN
approach enables high loading, highly efficient “encapsulation”, solvent-free processing,
and rational design of phytochemical release profiles.
4

CHAPTER II - UTILIZATION OF THIOL-ENE CHEMISTRY IN DRUG DELIVERY
APPLICATIONS
2.1 Thiol-ene “click” coupling/polymerization reactions
Thiol-mediated polymerizations, including radical, base, and nucleophile
catalyzed reactions, have emerged as valuable tools for the synthesis of a variety of
functional materials.31-35 The thiol-mediated reactions are attractive for developing
therapeutic delivery platforms since the reactions proceed under facile reaction conditions
(oxygen, water, and room temperature), possess rapid kinetics in high yield, do not
require expensive or potentially toxic catalysts, and are highly tolerant toward a wide
range of functional groups.33 The use of thiol-mediated chemistries has enabled the
formation of multiple therapeutic matrices exhibiting tunable release properties and
triggered responses from external stimuli. In this introduction chapter, we will provide a
brief overview of thiol-mediated reactions and their usage within controlled drug delivery
– covering topics such as therapeutic encapsulation, prolonged release, and release of
drugs from degradeable matrices.
2.1.1 Radical-mediated thiol-ene photopolymerization
The radical mediated thiol-ene reaction, which became popular after the
pioneering work of Hoyle 36-38, Khan 39-40, and Bowman41-43, is the reaction of a thiol
across an electron rich alkene in the presence of a radical initiator (thermal, photo, or
redox). Thiol-ene networks form via a free-radical step-growth polymerization of
multifunctional thiols and enes – facilitated by a rapid, highly efficient chain-transfer
reaction as depicted in Figure 2A. The initiating species is often generated via hydrogen
abstraction between a thiol and an activated initiator. The generated thiol radical then
5

adds across the double bond of an ene monomer generating a β-thioether carbon-centered
radical; the latter radical rapidly undergoes chain transfer with an additional thiol to
regenerate the thiol radical species. Termination then occurs via various recombination
reactions.44 Typical thiols that are commonly encountered in radical mediated thiol-ene
polymerizations include alkyl thiols, thiol propionates, thiol glycolates, and thiol phenols.
For each thiol, electron rich terminal alkenes (vinyl ethers and allyl ethers) and strained
alkenes (norbornene) react faster than electron defficient, internal, or substituted
alkenes.33 In drug delivery applications, the use of thiol-ene photopolymerization is
particularly attractive as it offers readily available biocompatible monomers with tunable
polymerization kinetics simply by controlling intensity or photoinitiator type. 45-46

6

Figure 2.1 Different initiation mechanisms for thiol-ene reactions: (A) radical mediated,
(B) base-catalyzed, and (C) nucleophile catalyzed.
2.1.2 Base and nucleophile-catalyzed thiol-ene polymerization
The base-catalyzed thiol-ene addition, or Michael addition, has found wide-spread
utility as a mild reaction strategy in both organic and polymer “click” reactions owing to
its high selectivity, rapid kinetics, and environmentally friendly reaction conditions (room
temperature, oxygen/light tolerant, low catalyst levels).47 Specifically, the base-catalyzed
Michael addition is an 1,4 addition which starts by deprotonation of a thiol by a sterically
hindered base (e.g. triethylamine) (Figure 2.1B). The thiolate ion attacks the β-carbon of
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an α,β-unsaturated carbonyl/sulfonyl resulting in a negatively charged enolate
intermediate, which undergoes chain transfer via the protonated catalyst or other thiol to
continue the process. The benefits of the thiol-Michael addtion (as mentioned previously)
have been exploited in the synthesis of click hydrogels for theraputic delivery under
aqueous conditions.48-49
Unlike the base-catalyzed pathway, the nucleophile-catalyzed pathway involves
direct reaction of a nucleophile (e.g. dimethylphenylphosphine) with an electron deficient
alkene to generate a strong base (Figure 2.1C). The generated base abstracts a hydrogen
from a thiol to form a thiolate anion which then follows the same addition and chain transfer
reactions as described for the base-catalyzed mechanism. Due to the limited water
solubility and high reactivity with metals and organic compounds, phosphine-catalyzed
reactions have not been used in the fabrication of hydrogels for cell incapsulation or drug
delivery. For a detailed description of the effect of different initiators/catalysts, a thorough
review on the advancements on thiol-Michael additions was published recently by
Bowman and coworkers.47
2.1.3 Thiol-ene step-growth vs. chain growth networks
Thiol-ene monomers can undergo either a step-growth polymerization mechanism
or a combination of step and chain growth polymerization. While parameters such as
initator type, cure intensity, and oxygen tolerance are critical for curing monomer, it is
the monomer structure (e.g. functional groups) and polymerization mechanism which
dictate the final macromolecular architecture of the three-dimensional polymer network.
It has been well established that networks formed via chain growth polymerization are
heteregeneous (with regions of high localized crosslink density – interspersed between
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regions of low crosslink density) due to the formation of different kinetic chain lengths,
cycles, and dangling chain ends (Figure 2.2A).50 Importantly, the polymerization of
multifunctional monomers such as acrylates, methacrylates, or styrenics, results in
repeating -C–C- linkages along the backbone of the crosslinked network rendering the
material nondegradable.51 Cleaveable linkages (ester, anhydride, acetal, ketal, etc.) can be
installed within the crosslinker to promote network degradation. Unfortunately, due to
chain growth network formation, the cleavage of the degradable linkages often leads to
long linear polymer fragments which may trigger an immune response.52-56

Figure 2.2 Differences between chain-growth (A) and step-growth (B) network
formation.
Alternatively, step-growth polymerization provides a superior method for the
formation of a homogeneous network. Multifunctional monomers (f > 2) with different
functional groups react in a stepwise fashion to form a crosslinked network with well
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defined molecular weight between each crosslink junction. The mechanism of stepgrowth polymerization ensures that any functionality (e.g. degradable linkages) in the
monomer will be present within the crosslink junctions of the network (Figure 2.2B). For
a step-growth network, exposure to a stimulus will trigger every crosslink junction to
cleave allowing for complete network degradation into small molecule constituents as
opposed to polymers/oligomers derived from chain-growth networks.
Specific to thiol-ene step-growth polymerizations, the alternating propagation
and chain transfer events of the polymerization process proceed rapidly and build
molecular weight in a uniform manner, but reach the gel-point only at relatively high
functional group conversions yielding defect-free polymer networks.57 The homogeneity
of the network is typically reflected by a narrow glass transition occurring over a range of
30 – 50 °C. Recently, Kim et al. compared the degradation of acetal-based networks
prepared via chain-growth (methacrylates) and step-growth (thiol-ene) polymerization.58
Upon network hydrolysis, the methacrylate network remained intact (long linear polymer
fragments did not degrade) while viscous flow was observed for the thiol-ene network
due to complete degradation into small molecule byproducts.
2.1.4 Drug delivery design via thiol-ene chemistry
Incorporation of a drug within a polymeric matrix can be classified into one of
two strategies: 1) traditional delivery, which relies on dispersing the drug within a
degradable or non-degradable polymeric matrix; and 2) poly(actives), in which the drug
is polymerized directly into the polymer backbone or covalently tethered to the backbone
(pendent) via degradable linkages (Table 2.1). These delivery strategies offer different
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release mechanisms, which can be governed by Fickian or non-Fickian diffusion, or a
combination of both.
Table 2.1 Thiol-ene based drug delivery platforms (potential and existing).

Delivery platform
Dispersed thermoplastic

Dispersed thermoset

Dispersed + degradable
thermoplastic

Dispersed + degradable
thermoset

Covalently attached
thermoplastic (pendent)

Release Parameters

Matrix Fate

Traditional delivery platforms
• Drug/polymer:
crystallinity, solubility, and
miscibility
Non-degradable
• Water permeability
• Polymer MW and Tg
• Drug/polymer: crosslink
density, solubility,
miscibility
Non-degradable
• Water permeability
• Tg
• Drug/polymer:
crystallinity, solubility,
miscibility
• Water permeability
Degradable
• Polymer MW and Tg
• Degradation rate of linker
in the environment
• Drug/polymer: crosslink
density, solubility,
miscibility
Degradable
• Water permeability
• Tg
• Degradation rate of linker
in the environment
Poly(actives)
• Drug/polymer:
crystallinity, solubility,
miscibility
• Water permeability
Non-degradable
• Polymer MW and Tg
• Degradation rate of linker
in the environment
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References

No examples to
date

Lignin59, thioether ester60

poly(thioether
ester)61-62

Anhydrides6364
, orthoester65,
chitosan-ester66

No examples to
date

Covalently
attached
thermoplastic
(main chain)

Covalently attached
thermoset

• Drug/polymer:
crystallinity, solubility,
miscibility
• Water permeability
• Polymer MW and Tg
• Degradation rate of linker
in the environment
• Drug/polymer: crosslink
density, solubility,
miscibility
• Water permeability
• Tg
• Degradation rate of linker
in the environment

Degradable

No examples to
date

Non-degradable

Disulfides and
esters,67

Degradable

acetals68-69

Active Networks
• Drug/polymer: crosslink
density, solubility,
miscibility
• Water permeability
• Tg
• Degradation rate of linker
in the environment

In designing effective drug delivery platforms for specific applications –
monomer selection, polymerization kinetics, incorporation of degradable/non-degradable
linkages, drug hydrophilicity/phobicity, crosslink density, crystallinity, glass transition
temperature (Tg), reaction byproducts and relevant degradation stimuli should be
carefully considered. In this section, we will discuss the advantages and disadvantages of
each strategy, followed by examples of drug delivery utilizing thiol-ene chemistry.
2.1.5 Passive delivery
Passive delivery relies on physically mixing/encapsulation of the drug within
either a non-degradable or degradable polymer matrix (thermoset and thermoplastic),
which mitigates the need of drug modification and improves the biostability and
bioavailability - especially for hydrophobic drugs. Polymeric matrices can be inert, in
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which the matrix behaves as a membrane with constant drug release, or swellable, in
which drug release is dependent on concentration gradients and degree of swellability.
2.1.5.1 Thermoplastics
Various non-degradable linear polymeric matrices such as poly(urethanes) and
poly(dimethylsiloxanes) have been highlighted in the literature and have been widely
used as drug-eluting medical implants; however, very few examples of drug eluting
poly(thioethers) exist in literature.61-62 In general, the release profile of drugs dispersed in
thermoplastics can be controlled via polymer molecular weight, crystallinity,
hydrophilicity/phobicity, swellability, and the presence/absence of degradable linkages.
Multiple papers have reported the synthesis of semicrystalline poly(thioethers)
with tunable crystallinity through traditional emulsion polymerization techniques.70-71
Additionally, direct incorporation of degradable esters and anhydrides have been
demonstrated within semicrystalline poly(thioether) backbones.72-74 These degradable
linkages allow the polymer chains to be broken down into di-acids and di-alcohols under
mild conditions. For instance, Cardosa et al. have directly polymerized a di-alkene
anhydride (1,3-propylene diundec-10-enoate) with 1,4-butanedithiol to yield degradable
linear poly(thioether) with number average molecular weights ranging from 5-20 kDa.75
These semicrystalline polymers have a melting temperature around 70 °C and exhibited
no observable cytotoxicity toward red blood cells even at 200 µg L-1.
Recently, Araújo and coworkers developed a linear poly(thioether ester)
platform61-62 based on butanedithiol and a dialkene synthesized via an esterification
reaction of 10-undecanoic acid with isosorbide. The monomers were polymerized via
radical-initiated miniemulsion polymerization, resulting in semicrystalline polymers with
13

molecular weights ranging from 2-11 kDa.62 Coumarin 6, a hydrophobic dye, was
encapsulated during the emulsification process with up to 98% efficiency and served as a
visual marker for cellular uptake. The nanoparticles displayed no observable cytotoxicity
at concentrations ranging from 10-200 µg mL-1 and are good candidates for a biomedical
nanomaterial. Araújo expanded this platform with the encapsulation of clove oil within
the poly(thioether ester) miniemulsion process.61 The nanoparticles obtained by
miniemulsion polymerization were formulated with clove oil varying from 0 to 25%
(w/w of monomer) with a ~98% encapsulation efficiency. The antioxidant, or radical
scavenging properties of the nanoparticles with only 6% clove oil demonstrated potent
antioxidant capabilities while preserving the bioactivity of the antioxidant rich clove oil
constituents (e.g. eugenol). The ability to rapidly generate libraries of materials under
facile reaction conditions necessitates future investigations into thiol-ene scaffolds as
drug delivery matrices. While Cardosa and Araújo have highlighted the use of
difunctional thiol and alkene monomers for direct preparation of linear poly(thioethers),
additional studies are needed to translate the use of these polymers into clinical studies in
vivo.
2.1.5.2 Thermosets
Tuning the degradation of and release from linear polymers remains a challenge
as degradation/release rates are determined by manipulating coupled parameters such as
drug/polymer crystallinity, drug/polymer molecular weight, polymer functionality,
swellability, and drug/polymer hydropathy. Alternatively, crosslinked (thermoset)
matrices offer unique opportunities to tailor the release of actives via manipulation of
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defined parameters such as monomer functionality, crosslink density, monomer
concentration, and monomer molecular weight.
Two of the most commonly used crosslinked thiol-ene based drug delivery
designs are hydrophilic (e.g. hydrogels) 76 and hydrophobic (e.g. low molecular weight
multifunctional thiols and alkenes) crosslinked networks77. In a recent review by Kloxin
et al., the design parameters for tuning the drug release from thiol-ene based hydrogels,
such as tuning mesh size and swellability, are discussed.76 While hydrophilic networks
primarily rely on swelling as a mechanism for drug release, hydrophobic thiol-ene
networks depend on either the diffusivity of the drug through the matrix or degradation of
cleavable linkages present within the backbone/side chain of the network.
2.1.5.2.1 Non-degradable thermosets
One key advantage to the direct encapsulation of drugs is that challenges such as
hydrophobicity, volatility, and chemical instability can be easily overcome. Direct
encapsulation via thiol-ene miniemulsion has recently been proven to be an effective
encapsulation technique. Tong et al. used a miniemulsion to copolymerize an allylfunctionalized-lignin with a multifunctional thiol in the presence of a hydrophobic dye (to
monitor release), hexadecane (hydrophobe), solvent, surfactant, and water (continuous
phase).59 The resulting nano-sized emulsions possessed high encapsulation efficiencies
and were able to release 40% of the dye within 48 h at pH 7.4. These nanoparticles
served as a primary example of utilizing materials found in nature for the controlled
release of hydrophobic molecules such as drugs/dyes. Recently, Amato et al.
demonstrated the direct sequestration of essential oil derivatives (carvacrol from oregano
and thymol from thyme) into crosslinked poly(thioether) nanoparticles via miniemulsion
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polymerization.60 The nanoparticles were loaded with relatively high efficiencies (>90%)
and exhibited a constant drug release (<5%) over a 24 h period. The necessity of a
hydrophobic matrix was pronounced, as high loadings, long-term delivery, and high
encapsulation efficiencies of essential oils could not be readily attainable within a
hydrogel.
Additionally, Shi and coworkers synthesized micron-sized oil-in-water thiol-ene
droplets for the sequestration of hydrophobic fragrance oils and dyes.78 The process
showed a remarkable encapsulation efficiency (91-96%), rapid polymerization kinetics
(<45 minutes) and the resulting capsules were relatively shelf-stable at 45°C for at least
one month. Heating the microcapsules to 100 °C pressurized the capsules, induced
rupture of the membrane, and subsequently released the fragrance. Emulsion focused
crosslinked thiol-ene platforms highlight the utilities of applying fast reaction kinetics to
rapidly encapsulate – and eventually release – hydrophobic drugs. However, these
emulsion-based delivery platforms are complicated due to the multiple additives used
during polymerization which can affect the release profile as well as biocompatibility.
Additionally, the previously mentioned studies have yet to systematically vary
parameters such as crosslink density (mesh size and Tg,), network hydrophobicity, or
drug solubility to control drug release and these parameters should be studied in the
future.
2.1.5.2.2 Degradable Thermosets
One of the most well-characterized hydrophobic drug delivery systems obtained
by thiol-ene polymerization is the poly(anhydride), which has been popularized by Shipp
et al.79 Photopolymerized poly(anhydride) thiol-ene networks have been shown to surface
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erode as seen in other poly(anhydride) materials.80-81 The erosion process is due to the
rate of anhydride degradation being faster than water ingress into the hydrophobic
polymer matrix. Aside from the rate of anhydride hydrolysis, two synergistic parameters
work together to limit water ingress: 1) high crosslink density achieved from low
molecular weight – multifunctional monomers; and 2) monomer hydrophobicity (e.g.,
absence of alcohols, amines, carboxylic acids, etc. typically found in hydrogels). It is a
common phenomenon within thiol-ene networks that as molecular weight between
crosslinks increases, the free volume, hole-size, and diffusivity of molecules through the
network increase.82 Additionally, reducing the number of hydrogen bond
donors/acceptors within the polymer structure is known to limit the water uptake of the
network and can therefore serve as another parameter to tune the release profile.
Regarding direct polymerization of degradable poly(anhydrides), Shipp and
coworkers synthesized a library of linear and crosslinked drug-loaded poly(thioether
anhydrides) with varying degrees of hydrophilicity, hydrophobicity, and crosslink
density.63 Shipp’s work highlighted that increasing the amount of tetrafunctional
crosslinker resulted in a delayed onset of degradation. Other work from Shipp and
coworkers involved the direct encapsulation of lidocaine within thiol-ene poly(anhydride)
networks of varying crosslink density.64 Results from the study showed minimal
differences in network degradation for networks prepared with 30, 20, and 10%
crosslinker, indicating that erosion of the material plays a greater role in the release of
lidocaine than drug diffusion out of the hydrophobic network.
The encapsulation and controlled release of other hydrophobic drugs, such as
doxorubicin and paclitaxel, are paramount because of the associated high toxicity and
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limited pharmacokinetics of the drugs. Tang and coworkers successfully entrapped
doxorubicin within a hydrophobic/degradable crosslinked thiol-ene poly(orthoester) via
reaction-induced nanoprecipitation.65 During nanoprecipitation, doxorubicin was loaded
into the nanogels with high drug loading efﬁciency greater than 70%. Release kinetics
were performed at pH 7.4 and 5.0 to highlight the rapid degradation of the pH triggered
hydrolysis of the orthoester. At pH 5.0, ~75% of doxorubicin was released within 24 h
and at pH 7.4, ~15% was released. Cheng et al. also encapsulated doxorubicin via
photopolymerization of N-maleoyl-functionalized chitosan and 1,4-butanediol
bis(3mercaptopropionate) in miniemulsions.66 The crosslinked emulsified particles
exhibited a doxorubicin encapsulation efficiency and loading level ranging from 76-82%
and 5.6-6.1%, respectively. To demonstrate a pH directed release, the doxorubicin-loaded
nanoemulsions were subjected to pH 7.4 and 5.5 – leading to ~30-40% and 55-80%
release, respectively, within 48 h. Additionally, the results from cellular uptake studies
suggested that the doxorubicin-loaded nanoparticles can serve as an extended/controlled
release delivery platform in which the particles slowly release doxorubicin outside cells
(pH 7.4) and release doxorubicin at higher concentrations when internalized in
endosomes/lysosomes (pH 4.5-6.5).
Other processing techniques, such as electrospinning, have also been used to
encapsulate/release drugs from crosslinked thiol-ene networks. Heise et al.83 UV-cured
electrospun crosslinked fibers, with poly(globalide), difunctional thiols (crosslinkers),
photoinitiators, and indomethacin (an anti-inflammatory drug). The fibers could swell in
organic solvents, such as dichloromethane (DCM), without dissolving, and were able to
be loaded either by direct incorporation of indomethacin into the resin or swelling neat
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fibers in concentrated indomethacin/DCM solutions. They found that the direct
incorporation method led to linear release, proportional to fiber degradation, whereas the
solvent swelled methods added physiosorbed drug to the surface – causing unwanted
burst release followed by gradual and sustained release.
2.1.5.2.3 Poly(active) thiol-ene materials
Poly(actives) are polymeric pro-drugs that undergo partial or complete degradation to
release active therapeutic agents (e.g., anti-inflammatory, antioxidant, antibiotic).84 Direct
attachment of a drug to a poly(active) affords many unique advantages such as the
alteration and control over the drug’s hydropathy, propensity to crystallize,
pharmacokinetics, dissolution/release rate, and potential cytotoxicity. The linker between
the drug and polymer scaffold can either be cleavable (pH, enzymatic cleavage,
temperature, electromagnet radiation, etc.) or highly stable (amides, ethers, thio-ethers,
etc.). For systems containing cleavable linkages, the rate of drug release is governed by
both the linker chemistry (linker type and hydropathy) and environmental conditions .
Additionally, the hydropathy and crosslink density of the polymer network in crosslinked
poly(actives) or crystallinity in linear poly(actives) will play a significant role in linker
degradation for processes such as hydrolysis and enzymatic degradation. Unlike
traditional hydrogels in which hydrolysis events are statistical throughout the gel,
hydrophobic networks must rely on the diffusion of water from the outside of the material
towards the center – leading to a gradient of hydrolysis events through the material.
Shen and coworkers synthesized a crosslinked poly[oligo(ethylene
glycol)fumarate-codithiodiethanol fumarate] micelle with a covalently attached
doxorubicin.67 The system involved a hydrophobic fumarate, a PEG-diol, and a disulfide19

diol, which creates linear hydrophilic/phobic domains interspersed between disulfides
and esters allowing for both pH and reduction triggered degradation. The degradable
poly[oligo(ethylene glycol)fumarate-codithiodiethanol fumarate] was crosslinked in
water via a one pot addition of doxorubicin-SH (synthesized with a hydrolysable
hydrazone linkage) and a dithiol crosslinker. During crosslinking, the system selfassembles into a micelle in which the doxorubicin is covalently attached to the core at
drug loading concentrations up to as high as 17.5 wt%. Importantly, when the crosslinked
particles were placed into pH 7.4 water, only 5% of doxorubicin was released in 48 h,
indicative of a high degree of covalent attachment of doxorubicin-SH during the
crosslinking reaction. Under pH 7.4 and 10 mM dithiothreitol (a reducing environment to
mimic the intracellular environment) only a 5% release of doxorubicin was observed.
However, when the particles were subjected to pH 5.8 in the absence of dithiothreitol,
~50% of doxorubicin was released in 48 h. This behavior suggests that the environmental
pH controls the rate of hydrazone hydrolysis of the doxorubicin linkage not the scaffold
degradation. The combination of dithiothreitol and a pH 5.8 environment resulted in
~70% doxorubicin release and micelle disassociation. In this system, pH was the
dominant factor in controlling doxorubicin release and serves as a model for how to
design crosslinked-covalently linked poly(actives) for triggered release applications.
Recently, Amato et al. have published on the covalent ligation of two aldehydes,
p-chlorobenzaldehyde68 and p-anisaldehyde69 into a poly(thioether acetal) network. Both
examples relied on the conversion of the aldehyde into a difunctional alkene monomer,
which was subsequently photopolymerized into a thiol-ene network. When the network
was submerged into acidic environments, the networks rapidly degraded into small
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molecule constituents (tetrafunctional alcohol and aldehyde). Similar to Shen’s work67,
the rate of acetal hydrolysis controlled the rate of aldehyde released and 100% release
occurred when the material completely dissolved into solution. Currently, few examples
exist of covalent attachment of drugs into hydrophobic thiol-ene networks; however,
unique opportunities exist in high performance sustained release systems in which
permanence is not a requirement.
2.1.6 Conclusion
Remarkable progress has been made in the design and characterization of
controlled drug-releasing materials prepared via thiol-ene chemistry. Many examples
presented in this introduction chapter have shown great promise in the delivery of model
hydrophobic drugs; these systems provide formulations for the delivery of application
specific cargo moving forward. However, multiple opportunities to tailor drug release
within well-defined thiol-ene networks remain unexplored, including monomer design,
crosslinker design, monomer functionality, crosslink density, hydrophobicity, and
thermal mechanical properties. Additionally, precise control over the release of
hydrophobic drugs from thiol-ene matrices remains a constant challenge that needs to be
addressed. Finally, the remarkable functional group tolerance and plug-in-play nature of
the thiol-ene monomers can lead to new fundamental network structure-drug release
relationships within crosslinked hydrophobic thiol-ene networks.
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CHAPTER III - DESTRUCTION OF OPPORTUNISTIC PATHOGENS VIA
POLYMER NANOPARTICLE-MEDIATED RELEASE OF PLANT-BASED
ANTIMICROBIAL PAYLOADS
3.1 Abstract
We report the synthesis of antimicrobial thymol/carvacrol-loaded polythioether
nanoparticles (NPs) via a one-pot, solvent-free miniemulsion thiol-ene
photopolymerization process. The active antimicrobial agents, thymol and carvacrol,
were employed as “solvents” for the thiol-ene monomer phase in the miniemulsion to
enable facile high capacity loading (~50% w/w), excellent encapsulation efficiencies (>
95%), and elimination of all postpolymerization purification processes. The NPs serve as
high capacity reservoirs for slow-release and delivery of thymol/carvacrol-combination
payloads that exhibit inhibitory and bactericidal activity (> 99.9% kill efficiency at 24h)
against gram-positive and gram-negative bacteria, including both saprophytic (Bacillus
subtilis ATCC 6633 and Escherichia coli ATCC 25922) and pathogenic species
(E. coli ATCC 43895, Staphylococcus aureus RN6390, and Burkholderia cenocepacia
K56-2). This report is among the first to demonstrate antimicrobial efficacy of essential
oil-loaded nanoparticles against B. cenocepacia – an innately resistant opportunistic
pathogen commonly associated with debilitating respiratory infections in cystic fibrosis.
Although a model platform, these results point to promising pathways to particle-based
delivery of plant-derived extracts for a range of antimicrobial applications, including
active packaging materials, topical antiseptics, and innovative therapeutics.
3.2 Introduction
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Microbial threats, particularly multidrug-resistant (MDR) bacterial strains and
other emerging pathogens, are greatly impacting public health, burdening healthcare
systems, and have potential to disrupt socioeconomic infrastructures in both developing
and industrialized nations. In the United States alone, the Center for Disease Control
estimates at least two million illnesses and 23,000 deaths are attributed to multidrugresistant bacterial infections each year. Annually, these cases account for approximately
$20 billion in excess health care costs and up to $35 billion in lost productivity due to
sick leave and hospitalizations.85 While Staphylococcus aureus and Pseudomonas
aeruginosa tend to dominate the MDR discussion, other microorganisms, such as
Burkholderia cepacia complex (Bcc), have emerged as opportunistic pathogens with
significant clinical importance in persons with cystic fibrosis (CF).86 Pulmonary
colonization with Burkholderia cenocepacia, the most common isolate of the 18 member
Bcc, results in severe respiratory infections in persons with CF and is associated with
high morbidity and mortality rates.87 Effective treatments for B. cenocepacia infections
are rare, as these bacteria exhibit high intrinsic resistance to most antibiotics.88 In
general, the MDR microbial threat extends far beyond the effect on humans, and
additionally impacts animal agriculture and veterinary medicine. The continuous
emergence of MDR pathogens and scarcity of new antimicrobial drug scaffolds in the
pharmaceutical discovery pipeline have led to growing interest in natural, plant-derived
extracts as alternatives to synthetic antibiotics.21 In this direction, essential oils (EOs) –
typically complex extracts from aromatic plants comprising mixtures of aldehydes,
terpenes and phenols – are well known to exhibit broad spectrum biological and
antimicrobial activity.89-90 With many EOs identified as “Generally Regarded as Safe”
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(GRAS), these extracts have been actively explored and continue to garner interest as
food preservatives and packaging constituents,91-92 textile fragrances,93 pesticides,94 and
other antimicrobial therapeutic applications.12, 27, 95
Monoterpene phenol isomers, carvacrol and thymol, are major constituents of
EOs extracted from oregano, thyme, and other plants belonging to the Lamiaceae family.
These isomers show antiviral, antifungal, and broad spectrum antibacterial properties
against both gram-negative and gram-positive bacteria, including MDR and biofilm
forming microorganisms.96-97 In one promising example, EO extracts containing
carvacrol and thymol as primary constituents were shown to inhibit the growth of several
environmental and clinical bacterial strains belonging to the B. cepacia complex.98 The
broad spectrum of activity of these isomers has been attributed to multiple modes of
toxicity; however, the primary site of toxicity is the cell membrane.97 In general, these
hydrophobic isomers act by partitioning into the cytoplasmic membrane leading to
increased permeability, depletion of proton gradients, and subsequent disruption of
adenosine triphosphate (ATP) synthesis. The collapse of the proton motive force and
depletion of the ATP pool eventually lead to cell death.
A major challenge for the practical application of carvacrol and thymol as
antimicrobial agents stems from the hydrophobicity (poor water solubility), volatility, and
instability of these EO constituents. Poor water solubility, in particular, limits the
bioavailability of these compounds and significantly lowers their biological and
antimicrobial activity, whereas volatility is problematic for achieving sustained release
and controlled delivery. To address these challenges, a variety of approaches have been
reported to encapsulate hydrophobic EO constituents as colloidal systems, including oil24

in-water emulsions, microemulsions, and nanoemulsions; molecular inclusion complexes;
lipid-based carriers (e.g. liposomes and solid lipid nanocapsules);99 and polymer-based
carriers (e.g. films, micro/nanocapsules, and nanoparticles).20-21, 100 Polymer
nanoparticles (PNPs) are advantageous in that they offer a highly flexible delivery
platform for antimicrobial applications, where nanoparticle properties (e.g. morphology,
bulk/surface composition, and size) are readily tunable using a variety of synthetic
approaches.101-104 In turn, these tunable PNP properties dictate important features such as
particle stability, surface interactions, and EO loading and release kinetics. In this
direction, researchers have successfully incorporated carvacrol, thymol, and other
phenolic EO constituents into various PNP matrices (chitosan,105 poly(lactide-coglycolide)23, 106, methylcellulose,107 and zein108) via emulsification-evaporation,23, 106
emulsification-solvent exchange,107 and nanoprecipitation108 methods. While these
examples demonstrate facile fabrication, encapsulation, and exhibit antimicrobial
activity, many suffer several deficiencies such as low EO loading (i.e. 3% w/w carvacrol
in chitosan matrix), poor EO encapsulation efficiencies (e.g. 14 – 31% carvacrol-in-water
emulsion and ionic gelation of chitosan),109 use of organic solvents during encapsulation
(acetone, ethanol, dichloromethane),23, 108 and burst release profiles of EO.23, 106
Miniemulsion polymerization is ideally suited for encapsulation of hydrophobic
payloads (e.g. lipophilic drugs, pigments, fragrances, inorganic nanomaterials, and
polymers) with high loading and encapsulation efficiencies,110-112 but has received little
attention for sequestration and delivery of essential oils – particularly towards
antimicrobial applications. Miniemulsion polymerizations are described as aqueous
dispersions of small, narrowly distributed monomer droplets stabilized against Ostwald
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ripening and collisional degradation by addition of an appropriate surfactant and
costabilizer.

Monomer droplets ranging in size from 50-500 nm are attained via high

shear mixing – typically either high-pressure homogenization or ultrasonic processing –
and subsequently serve as discrete nanoreactors for the formation of polymer
nanoparticles upon polymerization. Since mass transport between monomer droplets is
suppressed, encapsulation of hydrophobic materials requires a straightforward addition of
the desired material to the organic phase prior to shear mixing. Thus, encapsulation of
materials miscible with the monomer phase provides polymer nanoparticles with the
payload dispersed throughout the polymer matrix (whereas immiscible materials provide
a route to nanocapsules).112 Recently, we and others have reported thiol-ene113-116 and
thiol-alkyne117-118 polymerization in miniemulsion as a facile platform for the synthesis of
crosslinked polythioether nanoparticles with tunable particle sizes, tailorable network
properties, and clickable surface functionality. More importantly, we demonstrated the
ability to encapsulate hydrophobic inorganic nanoparticles within the polythioether
matrix with high efficiency without sacrificing the rapid polymerization kinetics and high
conversions provided by the thiol-mediated photopolymerization process.
Herein, we report a facile, one-pot approach to encapsulate monoterpene phenols
(carvacrol/thymol) within polythioether nanoparticles as a model, sustained-release
antimicrobial platform. We employ thiol-ene photopolymerization in miniemulsion for
rapid nanoparticle synthesis, where carvacrol and thymol serve as miscible
compatibilizers in the monomer phase enabling solvent-free encapsulation with high
loading capacities (33-66% w/w, EO relative to the NP) and excellent encapsulation
efficiencies (> 95%). The absence of solvent and use of a polymerizable surfactant
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eliminate the need for any post-polymerization purification steps. Release studies reveal
the polythioether nanoparticles function as sustained-release reservoirs for
carvacrol/thymol – discharging less than 4% of the payload over 24 h. The
thymol/carvacrol-loaded (TCNPs) nanoparticles show effective antimicrobial activity (>
99.9% kill efficiency at 24h) against gram-positive (Bacillus subtilis and Staphylococcus
aureus) and gram-negative (Escherichia coli and Burkholderia cenocepacia) bacteria.
Considering the innate resistance of the bacterial strain, the high efficacy of TCNPs against
Burkholderia cenocepacia is particularly significant, and to our knowledge, represents
the first demonstration of antibacterial efficacy against B. cenocepacia using
thymol/carvacrol-loaded polymer nanoparticles.
3.3 Experimental
3.3.1 Materials
Glycol di(3-mercaptopropionate) (GDMP) and pentaerythritol tetra(3mercaptopropionate) (PETMP) were provided by Bruno Bock. Hexadecane, ethyl acetate,
sodium chloride and thymol were obtained from Fisher Scientific. Diallyl phthalate
(DAP), 4-methoxy phenol (MEHQ), and butyl acetate were acquired from Sigma
Aldrich. Other reagents were purchased from the following vendors: 1hydroxycyclohexyl phenyl ketone (Irgacure 184) from CIBA; Hitenol BC-20 from
Montello, Inc.; carvacrol from TCI America. Difco Agar, Mueller Hinton II agar (MHA),
Mueller Hinton II broth (MHB), and Bacto Tryptone were from Becton, Dickinson and
Company. All the materials were obtained at the highest purity available and used
without further purification unless otherwise specified.
3.3.2 Characterization Methods.
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The size and distribution of the nanoparticles (NPs) were measured by dynamic
light scattering (DLS) using a Microtrac Nanotrac Ultra NPA150 particle analyzer.
Particle size and distribution were obtained using the Microtrac Flex software (v.10.6.1),
which employs non-negatively constrained least-squares (NNLS) and cumulants analysis
to obtain the intensity-weighted “z-average” mean particle size as the first cumulant, and
the polydispersity index from the second cumulant.119 Transmission electron micrographs
were taken with a Zeiss 900 electron microscope operating at 50 kV and outfitted with a
Model 785 Erlangshen ES1000W CCD camera (Gatan). Samples were applied to 200
mesh copper grids (3.05 mm, 200 lines per inch square mesh, EMS) coated with Formvar
(5% polyvinyl formal resin). Proton (1H) NMR was recorded on a Bruker Acend™ 600
MHz spectrometer at 30°C in D2O, using 128 scans and a 4.27 s relaxation delay. Optical
density (OD) and fluorescence readings were performed in a BioTek Synergy 2
programmable microplate reader. Confocal images were taken using a Zeiss LSM 510
confocal laser scanning microscope. High-resolution field emission SEM (FE-SEM) was
performed with a Zeiss SIGMA variable pressure field emission scanning electron
Microscope operating at 10 kV in high vacuum mode. Samples were sputter coated with
silver at instrument reported thickness of 5 nm with a Quorum Emitech K550X sputter
coater. Raman spectra were acquired using a high-performance portable Raman
spectrometer (i-Raman Plus, B&W Tek Inc., Delaware, USA). The samples were
analyzed at 100 mW, with a 785 nm diode laser and 150 s accumulation time.
3.3.3 General nanoparticle sample preparation.
Each nanoparticle reaction was prepared in a 20 mL scintillation vial with a total
volume of 10 mL. The organic stock solutions shown in Table A.1 were added into a vial
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containing a stock solution of 70 mM Hitenol BC 20 and deionized water. As we
previously reported, MEHQ serves as a radical inhibitor to suppress thermal
polymerization during ultrasonication.113 The samples were placed into an ice bath and
sonicated using a Qsonica Q700 probe ultrasonicator at 25% amplitude for 25 min. The
resultant miniemulsions were cured for 15 min at intensity of 185 mW cm−2 using an
OmniCure S1000 UV light source with a 100W mercury lamp (λmax = 365 nm, 320–500
nm filter). All samples were made in triplicate to ensure data reproducibility.
3.3.4 Preparation of essential oil encapsulated nanoparticles.
Carvacrol encapsulated nanoparticles were prepared by replacing butyl acetate
with 33% w/w carvacrol as the solvent. For nanoparticles containing a combination of
thymol and carvacrol, 20% w/w thymol was added along with 27% w/w carvacrol. The
total organic fraction evaluated was 4.5% w/w for all samples.
3.3.5 Determination of nanoparticle number density (particles/mL)

Vtotal  organic added

(1)

Where organic added is a known volume that can be converted into cubic nanometers.

4
Vsphere   (r ) 3 (2)
3

Where r, is the radius (nm) determined from light scattering.

Vtotal
 # particles
Vsphere

(3)

The final # of particles is determined by dividing the total volume of organic by the
volume of the average nanoparticle size (see Table A.2). This number results in
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particles/10 mL (10 mL is the total volume of the emulsified solution), multiplication of
volume added by this number results in # of particles delivered.
3.3.6 Gas chromatography-mass spectrometry (GC-MS) release study of essentials
oil nanoparticles.
Freshly prepared CNPs and TCNPs were transferred into 100 mL volumetric flasks
and diluted 1:10 with deionized water. For each diluted suspension, 10-mL aliquots were
removed at 0, 4, 8, 12, and 24 h, and NPs were precipitated for 4 h at 40,000 rpm (4°C) in
a Beckman Coulter Optima XE ultracentrifuge. 200 μL of the supernatant were removed
and extracted by vortexing for 30 s with 800 μL of ethyl acetate. The liquid phases were
separated by centrifugation for 15 min at 13,000 rpm, and the organic layer was
transferred to a capped 1.5 mL GC-MS vial. To determine the amounts of EOs in the preemulsified organic monomer mixture, 450 μL of organic stock solution (carvacrol and
combo) was diluted 1:100 in ethyl acetate. All samples were placed into capped GC-MS
vials and run using the following protocol.
GC-MS analysis was performed on an Agilent 6890 GC/MSD equipped with an
auto sampler and a Restek RTx-1 30 meter column. All samples and standards were
analyzed from 1 µL injection volumes. Analysis parameters include an inlet temperature
of 200 °C in splitless mode and a helium flow rate of 30 ml/min in gas saver mode.
Thermal ramping conditions used include an initial hold at 45 °C for 4 min followed by
an increase in temperature at 25 °C/ min. up to 140 °C with a 3 min hold at 140°C. The
temperature ramp continued at 2.5 °C/ min up to 150 °C with a 3 min hold followed by a
final increase at 50 °C/min to 220 °C with a 7.00 min hold (Figure A8). The method
provided unique separation of thymol and carvacrol isomers eluting at 19.41 and 19.58
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min respectively (Figure A9). Calibration curves for both isomers were prepared in ethyl
acetate at 0, 200, 400, 600, 800 and 1,000 ng µL-1 (Figure A10). A representative
chromatogram of extracted nanoparticles depicting the elution of thymol, carvacol and
hexadecane can be seen in Figure A11.
3.3.7 Evaluation of antibacterial activity of nanoparticles
The antimicrobial activity of NPs was tested against several species of bacteria
using a well diffusion method. The indicator microorganisms included
Escherichia coli ATCC 25922 (serotype O6, biotype 1), E. coli ATCC 43895 (serotype
O157:H7), Staphylococcus aureus RN6390,120 Bacillus subtilis
subsp. spizizenii ATCC 6633, and Burkholderia cenocepacia K56-2 (clinical isolate from
Canada)121. The testing was done on Mueller Hinton II agar (MHA) plates that have been
overlaid with soft agar seeded with individual bacterial strains. The soft agar contained
(per liter): 10 g of Bacto Tryptone, 6 g of Difco agar, and 8 g of sodium chloride. To
create an overlay, the indicator organisms were grown overnight at 27°C (B. subtilis) or
37°C (E. coli, S. aureus, and B. cenocepacia) in Mueller Hinton II broth (MHB). The
overnight cultures were diluted 1:5 with fresh MHB, and mixed with molten soft agar to
achieve the density of ~108 CFU mL−1. From this mixture, 4-mL aliquots were overlaid
onto MHA base plates and allowed to completely solidify.
After solidifying of soft agar, 8 mm wells were made, and their bottoms were
sealed with 20 µL of MHA. Then, 70 μL of each sample were added to the wells and
allowed to freely diffuse into growth medium. Wells containing pure carvacrol or a
mixture of carvacrol (1 g) with thymol (0.6 g) were used as a positive control. Negative
controls contained 70 mM Hitenol BC 20, or empty NPs suspended in butyl acetate. The
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plates were incubated at each bacterium’s optimum growth temperature as listed above.
The zones of inhibition (ZOI) were measured after 24, 48 and 72 h. Three replicates were
carried out for each nanoparticle treatment and bacterial strain. Experiment was repeated
three times to ensure data reproducibility.
3.3.8 Determination of Minimum Inhibitory Concentrations (MICs)
MICs of nanoparticles were determined using a modified broth microdilution
method122. Briefly, overnight bacterial cultures were adjusted to ~105 CFU mL-1, and
nanoparticles were serially diluted with sterile water to achieve a range of concentrations
between 1011 to 107 particles µL-1. In a 96-well microplate, 150 µL aliquots of adjusted
bacterial cultures were mixed with 50 µL aliquots of different NPs. Bacteria suspended in
MHB without addition of nanoparticles served as a positive control, while MHB without
bacterial inoculum and nanoparticles served as a negative control. The inoculated
microplates were incubated at each bacterium’s optimum growth temperature, and the
susceptibility of microorganisms to different NPs was assessed by measuring optical
density at 600 nm. The results were expressed as % viability obtained through equation 4:
% viability 

(ODt20 )  (ODt0 )
(ODt20 )

 100 (4)

Where OD is the optical density at 600 nm, t0 is the initial time 0 h, and t20 is the
time after 20 h of incubation.
For further verification of inhibition of bacterial growth, 10 µL of bacterial
cultures treated for 20 h with different nanoparticles were plated on MHA and incubated
at each bacterium’s optimum growth temperature for additional 20 h. The MIC refers to
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the concentration of NPs that completely inhibited bacterial growth. Each treatment had
four replications and experiment was repeated twice.
3.3.9 Viability staining assays
Bacterial viability was determined by using a LIVE/DEAD® BacLight™ Bacterial
Viability Kit staining kit (Life Technologies). Overnight bacterial cultures were
centrifuged at 8,500 rpm for 3 min, supernatants were removed and the bacterial cells
were suspended in 0.9 % NaCl at OD600 of 0.1 (~108 CFU/mL). Freshly prepared
nanoparticles were diluted 1:10 with sterile water. The adjusted bacterial cultures were
mixed with the diluted nanoparticles at a ratio of 3:1, and incubated at 20°C in the dark.
At 0, 2, 4, 6, 8, 12, and 24 h, 100 µL aliquots of the bacteria-NP mixtures were
transferred into a black flat bottom microplate, and mixed with 100 µL of the
LIVE/DEAD BacLight staining reagent. The samples were incubated in the dark for
15 min, and fluorescence was measured using a 485/20 nm excitation filter (for both
SYTO9 and PI) and a 528/20 nm (SYTO9 emission wavelength) and a 620/40 nm (PI
emission wavelength) emission filter. For confocal imaging, 5 µL of the stained sample
were cast on a microscope slide. Each sample was assayed in triplicate, and the
experiment was repeated twice. The results of viability staining were confirmed by
plating 10 µL of each bacterial suspension on MHA, and incubating the plates at an
appropriate growth temperature for 20 h.
3.3.10 Terminal dilution assays
To compare the rate of bacterial killing by different NPs, the test organisms were exposed
to NPs and the decline in numbers of viable bacteria was followed by a modified terminal
dilution method.123 The bacterial cultures were prepared and adjusted to ~108 CFU mL-1
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as described above. The adjusted bacterial cultures (9 mL) were mixed with nanoparticles
(1 mL), and the bacterial populations were determined immediately after the addition of
NPs (0 h), and at 2, 4, 8, 12 and 24 h of exposure. At each time point, 100-µL aliquots of
the bacteria-NP suspensions were transferred into 96-well microplates prefilled with 200
µL of MHB and serially diluted. The inoculated microplates were incubated for 48 h at
appropriate growth temperature, after which the turbidity in each well was measured with
a BioTek Synergy 2 microplate reader. An optical density at 600 nm of  0.05 was
considered positive for bacterial growth. Populations of viable bacteria were calculated
from the final dilution (terminal dilution, or TD), in which bacterial growth was observed
using equation 5:
CFU
mL

=

10×3TD
1mL

(5)

Where TD is the terminal dilution factor obtained from microplate readings.

3.4 Results and Discussion
3.4.1 Synthesis and characterization of essential oil encapsulated nanoparticles
Polythioether NPs loaded with various ratios of carvacrol/thymol were synthesized
via thiol-ene photopolymerization in miniemulsion according to Figure 3.1a. NPs were
prepared by dispersing the organic phase, comprising diallyl phthalate (DAP), glycol di(3mercaptopropionate) (GDMP), pentaerythritol tetra(3-mercaptopropionate) (PETMP), and
carvacrol/thymol, into deionized water containing surfactant via probe ultrasonication for
25 min (Figure 3.1b). The full details for the miniemulsion formulation are given in Table
S1. The monomer droplets were then photopolymerized by exposure to UV light (λmax
365nm). Control NPs (without carvacrol/thymol) were similarly prepared using butyl
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acetate as a diluent for the organic phase. After ultrasonication and photopolymerization,
aliquots were removed and analyzed via 1H NMR (Figure A.1) in D2O. The disappearance
of the peaks attributed to the thiol (–CH2CH2–SH, 2.62-2.83 ppm) and alkene (5.07-5.45,
5.87-6.10 ppm) from the monomers, and broadening of other peaks indicated the thiol-ene
photopolymerization proceeded to high conversion. Additionally, Raman spectroscopy of
freshly emulsified nanoparticles prior to and after UV polymerization showed the
disappearance of SH (2580 cm-1) and alkene stretches (1640-1680 cm-1) (Figure A.2). The
ability to achieve high thiol-ene monomer conversion in the presence of phenolic
functional groups is in good agreement with our previous work.117,

124-125

At near

quantitative conversions, crosslink density (0.168×10-3 mol/cm3) of the polythioether NPs
was estimated from the rubbery plateau storage modulus (1.25 MPa, Tg -12.1 °C, Figure
A.3) of the base thiol-ene resin (i.e. GDMP+PETMP+diallyl phthalate prepared at identical
stoichiometric ratios used in the miniemulsions) at Tg + 40 °C according to the theory of
rubber elasticity.126 To eliminate surfactant leaching, Hitenol BC-20 was employed as a
polymerizable surfactant to covalently incorporate the surfactant into the thiol-ene network
(discussed further in the antimicrobial section). A series of exploratory NP syntheses were
conducted, in which the concentration of Hitenol BC-20 (Figure A.4a) and organic weight
fraction (Figure A.4b) were independently varied, to identify conditions to provide
acceptable NP size and size distributions. A 4.5 wt.% organic phase and 70 mM Hitenol
BC-20 were identified as optimum parameters; these conditions provided pure carvacrolloaded NPs (CNPs), thymol/carvacrol-loaded NPs (TCNPs), and control NPs with mean
particle sizes of 148 ± 24 nm (PDI: 0.560), 147 ± 19 nm (PDI: 0.387), and 183 ± 19 nm
(PDI: 0.473), respectively, as determined by DLS (Figure A.3). We note that the reported
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std. dev. values represent the deviation in the average particle size obtained from a
minimum of three separate syntheses. A representative transmission electron microscopy
(TEM) image for TCNPs loaded with a 0.75:1 T/C ratio (Figure 3.1c) showed spherical
particles with sizes in good agreement with DLS analysis. TEM for the control NPs and
CNPs are shown in Figure A.5a and A.5b, respectively. The salient feature of this synthetic
approach is that the carvacrol/thymol constituents serve as the “solvent” for the organic
phase in the miniemulsion process.

This route enabled a high loading capacity of

thymol/carvacrol within the NPs (between 33 – 66% w/w, EO/NP) with high encapsulation
efficiencies (>95% by GC-MS), eliminated the need for an organic solvent during NP
synthesis, and provided a one-pot approach to EO encapsulation without any postpolymerization purification processes (e.g. no freeze drying, evaporation, extraction
processes were required). Thus, the NP dispersions obtained from the previously described
synthetic approach were used directly for the antimicrobial studies detailed below.

Figure 3.1 (A) The thiol-ene reaction involves alternating chain transfer and propagation
(B) with various multifunctional monomers used to generate polythioether nanoparticles
via thiol-alkene photopolymerization in miniemulsion. (C) Representative TEM of
thymol/carvacrol-loaded nanoparticles.
3.4.2 Loading and Release of Thymol and Carvacrol
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Next, we investigated the release kinetics of carvacrol and carvacrol/thymol
mixtures released from polythioether NPs into water. The amount of essential oil released
was quantified by measuring the concentration of carvacrol/thymol available in water via
GC-MS at 0, 4, 8, and 12 h. Figure 3.2a shows the release data for CNPs (synthesized at
33% w/w C/NP) and TCNPs (synthesized with 47% w/w TC/NP, 0.75:1 T:C). The EOload
data points represent the total amount of carvacrol (16 ± 0.7 mg/mL) and thymol/carvacrol
(25 ± 5 mg/mL) loaded into the NPs during miniemulsion photopolymerization, and are
in good agreement with initial formulations for each type of NP. The ratio of the time 0
and EOload concentrations represents the encapsulation efficiency for the miniemulsion
process, i.e. ~96.9% for TCNPs and 96.8% for CNPs. Thus, the concentration of EO within
the nanoparticles is up to 20 times higher than the reported solubility limits for thymol
(0.85 mg/mL) and carvacrol (1.25 mg/mL) at 20 °C.127 As shown in Figure 3.2a, the
concentration of EO released from the NPs in water was relatively constant over 24 h,
where TCNPs and CNPs reached plateau concentrations between 0.7-0.9 mg/mL and 0.5–0.6
mg/mL, respectively. These concentrations correspond to less than 4% release of the total
EO payload over 24 h, (Figure 3.2b) and approach the solubility limit of thymol and
carvacrol in water at 20 °C. These results suggest that the polythioether nanoparticles
effectively serve as a reservoir for the hydrophobic carvacrol and thymol compounds. This
“reservoir effect” enables extended delivery of EO constituents into the bulk aqueous
phase, where the solubility limit of the relatively insoluble compounds ultimately dictates
the aqueous-phase equilibrium concentration.
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Figure 3.2 (a) Amounts of essential oils extracted from the supernatant after pelleting
NPs by ultracentrifugation. (b) Calculated release profiles for both CNPs and TCNPs over
24 h.
3.4.3 Antimicrobial properties
Antimicrobial activity of the EO-containing NPs was evaluated against a panel of grampositive and gram-negative bacteria that included both saprophytic (B. subtilis ATCC 6633
and E. coli ATCC 25922) and pathogenic species (E. coli ATCC 43895 [serotype
O157:H7], S. aureus RN6390, and B. cenocepacia K56-2). Our preliminary experiments
revealed that control NPs prepared using either sodium dodecyl sulfate or
cetyltrimethylammonium bromide as surfactant exhibited antimicrobial activity,
presumably due to surfactant leaching. Thus, we chose Hitenol BC-20 – a commercially
available polymerizable surfactant – for further experiments, as it exhibited no measurable
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antimicrobial activity in zone of inhibition (ZOI) experiments at the concentration used in
NP synthesis (70 mM Figure 3.3a; 140 mM Figure A.6). More importantly, control NPs
prepared with Hitenol BC-20 showed no measureable ZOI against all five bacteria (Figure
3.3b).
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Figure 3.3 Well diffusion assay identifies treatments with antimicrobial activity. Bacteria
were incubated with 70 mM Hitenol BC-20 (a), ControlNPs (b), CNPs (c), and TCNPs (d) at
1013 NPs mL-1. Zones of inhibition (ZOI, mm) are reported below each image.
Initially, we evaluated the antimicrobial activity of NPs containing pure carvacrol
(33% w/w, carvacrol relative to NP) and various ratios of thymol:carvacrol (Treatment I –
66% w/w, 3:1 T:C; Treatment II – 55% w/w, 1.5:1 T:C; and Treatment III – 47% w/w,
0.75:1) against E. coli ATCC 25922, S. aureus RN6390, and B. subtilis ATCC 6633
(Figure A.7). Since thymol is a solid at room temperature (mp 49-51 °C), thymol-loaded
NPs were difficult to synthesize using a solvent-free approach and were not actively
pursued in this work. Previous reports have shown that combinations of thymol and
carvacrol exhibit higher antimicrobial activity than each individual constituent,97 thus,
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carvacrol-loaded NPs were evaluated via ZOI only as a comparison to NPs loaded with
combinations of thymol/carvacrol. Interestingly, all treatments with NPs containing
thymol/carvacrol showed similar zones of inhibition (Figure A.7), thus treatment III, with
the lowest overall thymol/carvacrol loading, was chosen for the experiments discussed
hereafter. From this point forward, the acronym TCNP will refer to nanoparticles loaded
with 47% w/w, 0.75:1 T:C (treatment III). Figure 3.3c and 3.3d show the results of well
diffusion assays for CNPs and TCNPs against the full panel of bacteria. As shown in Figure
3.3c, CNPs exhibited moderate activity against all bacteria (ZOI 1 – 2 mm). As expected,
TCNPs were consistently more effective than CNPs, as indicated by the larger ZOIs shown in
Figure 3.3d. TCNPs inhibited the growth of all five bacteria, including S. aureus (2 mm
ZOI) and B. cenocepacia (3 mm ZOI) that are known to exhibit high intrinsic resistance to
conventional antibiotics. Bacillus subtilis (6 mm ZOI) was the most susceptible species to
the TCNP treatment.
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Figure 3.4 Percent viability of various bacteria upon treatment with TCNPs. Inset images
show the corresponding spot tests for the presence of live bacteria.
The antimicrobial activity of TCNPs was further evaluated via determination of the
minimum inhibitory concentration (MIC). The MIC is defined as the lowest concentration
of an antimicrobial agent that inhibits the growth of a microorganism following an
overnight incubation period. We adopted a modified broth microdilution method to
determine MICs for NP-loaded thymol/carvacrol.122 We also spot-plated bacteria that were
incubated with NPs to check for possible bacteriostatic effects. While MIC assays are
reputable for accuracy and standardized comparison across numerous antibiotics, the
conventional MIC output presents a challenge for hydrophobic antibiotics encapsulated in
polymer nanoparticles – and is particularly problematic for NP delivery systems that
function via the “reservoir effect”. As a result of the “reservoir effect”, the concentration
loaded in the nanoparticle may be orders of magnitude greater than the concentration
delivered to the bacteria during the timeframe of the MIC assay. For example, the loaded
concentration of thymol/carvacrol in TCNPs was determined to be 25,000 μg/mL by GCMS. These thymol/carvacrol loading levels are up to 100-fold higher than reported MIC
values for E. coli 25922 (MICcarvacrol: 225 μg/mL, MICthymol: 225μg/mL) and S. aureus
(MICcarvacrol: 450 μg/mL, MICthymol: 225 μg/mL);128 however, our release studies show that
carvacrol and thymol are delivered to the bulk aqueous phase at a relatively constant
concentration of 500 – 900 μg/mL over 24 h. Following the precedent of Langer et al.,129
who previously noted the difficulty in defining the MIC for antibiotic-loaded nanoparticles,
we report concentrations as the total EO concentration within the NP at the beginning of
the treatment to identify the MIC. While the loaded concentrations grossly overestimate
the MIC value relative to a conventional definition, we reasoned this route of reporting was
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the most useful and conservative measure of NP-loaded antimicrobial efficacy.
Additionally, we calculated the nanoparticle number density (#particles/mL) to estimate
the number of NPs delivered in each experiment as an alternate MIC output value, with the
caveat that the number density is based on the average particle diameter of a polydisperse
nanoparticle population. Nonetheless, number density MIC provides a point of comparison
among the various bacteria investigated in this paper. Figure 3.4 shows the results from
the viability assays used to determine the MICs for TCNPs. In general, the growth of all
five bacteria included in this study was completely inhibited upon exposure to TCNPs loaded
at 25,000 μg/mL (1010 nanoparticles) in a 50 µL broth volume, which translated to
approximately 105 NPs per bacterial cell. B. subtilis was the most susceptible species, and
was completely inhibited at TCNPs loaded at 2,500 μg/mL (109 nanoparticles, ~104 NPs per
cell). The MIC values are in good agreement with the previously described results of agar
well diffusion tests.
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Figure 3.5 Effect of TCNPs on the viability of (a) B. subtilis ATCC 6633 and (b) E. coli
ATCC 25922, as monitored by confocal laser scanning microscopy. Representative
images of control cultures (top row), and cultures treated with 1011 TCNPs (middle and
bottom row) at the indicated time points. The green signal (SYTO 9) indicates viable live
cells, whereas red signal (propidium iodide) indicates damaged or dead cells. Scale bars
= 10 µm.
We also investigated the kill kinetics for the panel of bacteria incubated with TCNPs
using live/dead and terminal dilution assays. Initially, the kill kinetics of TCNPs against B.
subtilis ATCC 6633 and E. coli ATCC 25922 were probed using a live/dead cell viability
assay, which stains “dead” bacteria red upon cell membrane damage and uptake of
propidium iodide. As shown in Figure 3.5a and 3.5b, a large number of viable bacterial
cells (stained green) were observed for the B. subtilis and E. coli control samples,
respectively. Incubation of TCNPs with B. subtilis for 15 min yielded an apparent 50:50
live/dead ratio, whereas 30 min resulted in mostly dead bacteria (Figure 3.5a). For
E. coli ATCC 25922, the 50:50 live/dead ratio was observed after two hours of incubation
with TCNPs, and most bacteria stained dead after 8 h of incubation (Figure 3.5b). To
quantify the kill kinetics for all five bacteria, we used a terminal dilution assay. Figure
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3.6a shows the log reduction in the bacteria count as a function of incubation time with
~1011 TCNPs. The log CFU reductions at 48 h are reported as % kill values in Figure 3.6b.
In agreement with our previous ZOI data, B. subtilis ATCC 6633 showed the highest
susceptibility to the TCNP treatment with 4.3 and 7.1 log reductions observed at 12 and 24
h, respectively. The log reductions for E. coli O157:H7 (ATCC 43895) were 3.5 at 12 h
and 7 at 24 h – results that translate into a kill efficacy of > 99.99%. The viability of E. coli
ATCC 25922 declined at a slower rate than E. coli O157:H7, however, the 48-hour
exposure to TCNPs ultimately killed > 99.99% of the bacteria. Incubation of TCNPs with B.
cenocepacia K56-2 produced 3.9 and 6.2 log reductions at 12 and 24 h, respectively. The
kill kinetics and high susceptibility (over 99.99% efficacy at 24 h) of B. cenocepacia to the
TCNPs is of particular interest, as these bacteria have very high innate resistance to a wide
range of antibiotics and biocides.130 With a 3.6 log reduction, S. aureus RN6390 was the
only species that maintained viability after 24 h incubation with TCNPs. However, a 6.3
log reduction, or > 99.99 % kill efficacy for S. aureus was ultimately attained at 48 h.
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Figure 3.6 Evaluation of antimicrobial activity for 1011 TCNPs/mL on the viability of
() E. coli ATCC 25922, () S. aureus RN6390, () B. subtilis ATCC 6633, () E.
coli ATCC 43895 (serotype O157:H7), and () B. cenocepacia K56-2 via (a) a kinetic
terminal dilution and (b) percentage of bacteria killed and over 48 h. *Dashed line
represents the limit of quantitation.
Finally, insight into the antimicrobial mechanism was investigated by visualizing
the microbial structure of B. subtilis ATCC 6633 and E. coli ATCC 25922 before and after
prolonged contact with TCNPs using electron microscopy. Prior to exposure to TCNPs, TEM
of both microbes showed intact cell structure (Figure 3.7, control). After exposure with
TCNPs, distinct indication of damage to the cell envelope (diffuse membrane, cellular
debris) and loss of flagella were visible in both E. coli ATCC 25922 (Figure 3.7a) and B.
subtilis ATCC 6633 (Figure 3.7b). Additionally, the scanning electron microscopy (SEM)
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image of B. subtilis after 24 h exposure to inhibitory concentrations of TCNPs showed
bacteria with crumpled cell envelopes and pore-like lesions, which is consistent with the
collapse of the cell structure (Figure 3.7c). These results are consistent with previously
reported postulates that identify the cell membrane as the primary site of toxicity for
carvacrol/thymol.97
(a) E. coli ATCC 25922

(b) B. subtilis ATCC 6633

Control

Control

2h

1h

8h

2h

(c) B. subtilis ATCC 6633

1 µm
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Figure 3.7 (a) TEM of E. coli ATCC 25922 and (b) B. subtilis ATCC 6633 control
cultures and cultures that were challenged with 1011 TCNPs for various times. (c) High
resolution SEM of the control culture of B. subtilis ATCC 6633 and the culture treated
for 24 h with 1011 TCNPs.
3.5 Conclusions
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We have reported a one-pot, solvent-free miniemulsion photopolymerization process for
the synthesis of thymol/carvacrol-loaded polythioether nanoparticles.

Using the

thymol/carvacrol payload directly as a diluent for the monomer phase in the presence of a
polymerizable surfactant provided the active NPs without any post-synthetic purification.
The NPs serve as high capacity reservoirs for slow-release and delivery of
thymol/carvacrol-combination payloads that exhibit inhibitory and bactericidal activity (>
99.9% kill efficiency at 24h) against gram-positive (Bacillus subtilis and Staphylococcus
aureus) and gram-negative (Escherichia coli and Burkholderia cenocepacia) bacteria. The
simplicity, modularity, and efficacy of the essential oil encapsulation platform may combat
bacteria with intrinsic resistance to conventional antibiotics, and is potentially adaptable
for delivery of EOs as active packaging materials and topical antiseptics. The antimicrobial
activity of TCNPs against inherently resistant Burkholderia cenocepacia may provide a
route to innovative pulmonary therapeutics by appropriately engineering the nanoparticle
properties; investigations of thymol/carvacrol-loaded NPs against B. cepacia complex
biofilms – a challenging form of the bacteria commonly associated with cystic fibrosis –
are currently underway. In this direction, we are particularly interested to exploit the
simple synthetic modularity of this process for the design of EO-loaded biodegradable
nanoparticles with specific surface chemistries to serve as multimode (e.g. contact biocidal,
targeted NP-bacteria interactions) antimicrobial platforms.
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CHAPTER IV - PRO-ANTIMICROBIAL NETWORKS VIA DEGRADABLE
ACETALS (PANDAS) USING THIOL-ENE PHOTOPOLYMERIZATION
4.1 Abstract
We describe the synthesis of pro-antimicrobial networks via degradable acetals
(PANDAs) as a new paradigm for sequestration and triggered release of volatile,
bioactive aldehydes. PANDAs derived from diallyl p-chlorobenzaldehyde acetal degrade
and release p-chlorobenzaldehyde as an antibacterial and antifungal agent under mild
conditions (pH 7.4/high humidity). We show that PANDAs enable facile access to
materials with tunable release profiles, potent antimicrobial activity without triggering
antimicrobial resistance, and minimal cytotoxicity.
4.2 Introduction
With 700,000 annual deaths globally, antimicrobial resistance is an escalating
crisis that threatens the sustainability of public health and agricultural ecosystems.131 As
the effectiveness of antibiotics has precipitously declined, a growing interest in
alternative antibiotic scaffolds has proliferated. In this direction, aromatic terpene
aldehydes – major phytochemical constituents of plant derived essential oils (EOs) − are
known to exhibit potent and broad spectrum antibacterial and antifungal activities in both
liquid and gaseous states.132-133 However, practical application of terpenes remains a
challenge stemming from their poor water solubility, volatility, and chemical instability.
Many strategies have been reported to sequester or encapsulate terpenes within films or
colloidal systems;134-135 however, these strategies often suffer deficiencies such as low
loading, poor encapsulation efficiencies, necessity of organic processing solvents, and
uncontrolled burst release profiles.136
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“Polyactives” − polymeric pro-drugs that undergo degradation to release active
therapeutic agents − address the deficiencies in sequestering EO constituents by
providing high loading, chemical stability, and tailored release kinetics.84 Recently, linear
polyactives of phytochemicals and other synthetic analogs have been used for the
extended delivery of antimicrobials,27, 137 antioxidants,26, 138 anti-inflammatories,25
hormones,139 and anti-cancer therapeutics.140-141 While successfully demonstrated, tuning
the degradation of linear polyactives remains a challenge as degradation rates are
determined by manipulating coupled parameters such as crystallinity, polymer molecular
weight, functionality, and hydropathy.142 Alternatively, crosslinked polyactives (i.e.
thermosets) offer unique opportunities to tailor release profiles by simple manipulation of
crosslink density, monomer concentration, or monomer molecular weight.143 Recently,
Matras and Chatterjee developed biodegradable crosslinked polyactive esters that
challenge the performance of traditional linear polymers by offering greater control over
degradation rates, mechanical properties, and release kinetics.144 Although these
crosslinked polyesters showed high biocompatibility and are capable of releasing
anticancer, anti-inflammatory, or antimicrobial compounds,145-147 the lengthy
polymerization times (>1 day) at elevated temperatures (>130 °C) preclude
polymerization in the presence of cells, in vivo, or in 3D printing applications.
Furthermore, polyesters with sustained degradation typically exhibit localized
accumulation of acidic byproducts leading to inflammatory response.148 Polyactive
acetals are promising alternatives as acetals readily hydrolyze under mild aqueous
conditions into pH neutral byproducts (alcohols and aldehydes).149
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Inspired by polyacetal hydrogels,150-151 the work herein describes the synthesis of
pro-antimicrobial networks via degradable acetals (PANDAs) derived from pchlorobenzaldehyde (pCB) using thiol-ene photopolymerization – an approach designed
to address many of the aforementioned challenges with sequestration of terpene
aldehydes. Thiol-ene photopolymerization offers rapid cure kinetics at room
temperature, low oxygen inhibition, homogeneous network formation, and high monomer
conversion.152 Thiol-ene – as a step-addition polymerization – ensures that nearly every
crosslink junction contains a degradable, pCB-derived acetal. Therefore, PANDAs are
molecularly designed to undergo complete degradation upon hydrolysis resulting in the
release of pCB as an active antimicrobial and antifungal agent, and the generation of
inactive low molecular weight degradation byproducts (Figure 4.1).

Figure 4.1 Synthesis of PANDAs and major degradation byproducts.
4.3 Experimental
4.3.1 Materials
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Allyl alcohol, triethylamine (TEA), 4-chlorobenzaldehyde (pCB), 1,3,5-triallyl1,3,5-triazine-2,4,6 (1H, 3H, 5H) trione (TTT), 2-hydroxy-2-methyl-1-phenyl-propan-1one (Darocure 1173), p-toluenesulfonic acid (pTSOH), molecular sieves (3Å), dry
tetrahydrofuran (THF), hexane and ethyl acetate were acquired from Fisher Scientific.
Pentaerythritol tetra(3-mercaptopropionate) (PETMP) was provided by Bruno Bock.
Difco Agar, Mueller Hinton II agar (MHA), Mueller Hinton II broth (MHB), and Bacto
Tryptone were from Becton, Dickinson and Company. All the materials were obtained at
the highest purity available and used without further purification unless otherwise
specified.
4.3.2 Characterization Methods.
1

H NMR was recorded on a Varian Mercury Plus 300 MHz NMR spectrometer in

chloroform-d. Dynamic mechanical analysis (DMA) was performed using a TA
Instruments Q800 dynamic mechanical analyzer in tension mode equipped with a gas
cooling accessory. Samples were clamped and tested at a strain of 1 %. Samples were
heated from -80 °C to 90 °C at a ramp rate of 3 °C min-1. Kinetic data were obtained
using real-time FTIR (RT-FTIR) spectroscopy by determining the conversions of the
thiol and ene functional groups. The RT-FTIR studies were conducted using a Nicolet
8700 FTIR spectrometer with a KBr beam splitter and a MCT/A detector with a 320–500
nm filtered ultraviolet light source. Each sample was exposed to a UV light with an
intensity of 200 mW cm-2. Series scans were recorded, where spectra were taken
approximately 2 scan/s with a resolution of 4 cm-1. Thiol conversions was monitored with
integrating the SH conversion peak between 2500-2620 cm-1 while the conversion of the
allyl group was monitored with conversion peak between 3050-3125 cm-1. Optical
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density (OD) and fluorescence readings were performed in a BioTek Synergy 2
programmable microplate reader.
4.3.3 Synthesis of p-chlorobenzaldehyde diallylacetal (pCBA)
pCB (10 g, 71.14 mmol, 1 equiv), pTSOH (4.3 g, 24.97 mmol, 0.35 equiv), 3Å
molecular sieves (15 g), and allyl alcohol (16.52 g, 284.6 mmol, 4 equiv) were dissolved
in dry THF (50 mL). The yellow reaction mixture was left to stir overnight and then
quenched with addition of TEA (19.8 mL, 142.3 mmol, 2 equiv), filtered and rotovapped
before adding to a silica gel column. The column was eluted with a 10:90 (v:v) ethyl
acetate/hexane mixture to afford 8.3 g (48.9%) of the acetal. 1H NMR (300 MHz,
Chloroform-d) δ 7.46 (d, J = 8.4 Hz, 1H), 7.36 (d, J = 8.4 Hz, 1H), 5.95 (ddt, J = 16.2,
10.8, 5.6 Hz, 1H), 5.63 (d, J = 2.7 Hz, 1H), 5.33 (dt, J = 17.2, 1.8 Hz, 1H), 5.20 (dd, J =
10.5, 2.1 Hz, 1H), 4.06 (d, J = 5.1 Hz, 2H). 13C NMR (75 MHz, CDCl3) δ 136.97,
134.27, 128.41, 128.21, 116.96, 99.63, 66.06. GC-MS observed: 238; calculated: 238.
4.3.4 General preparation of PANDA disks
The 100% pCBA disks were prepared by adding PETMP and pCBA at 1:1 ratio
of SH:alkene, along with 4 wt % of Darocure 1173. The 90% pCBA disks were prepared
by adding pCBA and TTT as another source of alkene (TTT is 10% of total alkene while
maintaining an overall 1:1 ratio of alkene:SH) with PETMP, and Darocure 1173. The
mixtures were well mixed and 25 μL of monomer formulations were aliquoted onto a
glass slide and covered with another glass slide spaced with Teflon spacers (0.76 ± 0.02
mm in thickness). The samples were then cured using an Omnicure S1000-1B with a
100W mercury lamp (λmax = 365 nm, 320–500 nm filter) at an intensity of 200 mW
cm−2 for 20 minutes.
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4.3.5 Degradation of PANDAs in Phosphate Buffer Saline (PBS)
The hydrolysis of PANDA disks was done using a slight modification of a
method reported by Carter and coworkers.151 In general, the degradation study was
performed in aqueous media (PBS) at pH 7.4 with a large excess of octanol to partition
the aldehyde from the aqueous environment. Concentration was determined by measuring
the absorbance of pCB released at 275 nm over 120 hours and extrapolated from a
standard calibration curve. Experiments were done with n=5, with the mean and standard
deviation reported. The 25 mm3 disks were placed at the bottom of 20 mL scintillation
vials filled with 3 mL of PBS and 15 mL of octanol. Immediately, 100 μL octanol
aliquots were taken out form the vial and measured for t=0. After the measurement,
aliquots were placed back to the scintillation vials to maintain the same concentration
throughout the kinetic study. Aliquots were analyzed at t = 0, 20, 24, 30, 48, 54, 72, 78,
96, 102, 120 h.
4.3.6 Degradation of PANDAs in HCl, H2O, and NH4OH chambers
Humidity chambers were made via bubbling nitrogen gas into a vial containing
either 12 M HCl, 30 wt% NH4OH, or deionized H2O. A cannula in the head space of the
pressurized vial allowed transport into a secondary vial containing a 90% pCBA PANDA
disk on a glass slide.
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4.3.7 Evaluation of antibacterial activity of PANDAs
The antimicrobial activity of PANDA disks was evaluated against several species
of bacteria via the zone of inhibition method. The indicator microorganisms included
E. coli ATCC 43895 (serotype O157:H7), Staphylococcus aureus RN6390, Burkholderia
cenocepacia K56-2 (clinical isolate from Canada), and Pseudomonas aeruginosa PA-01.
The testing was done on Mueller Hinton II agar (MHA) plates that were overlaid with
soft agar seeded with individual bacterial strains. The soft agar contained (per liter): 10 g
of Bacto Tryptone, 6 g of Difco agar, and 8 g of sodium chloride. To create an overlay,
the indicator organisms were grown overnight at 37°C in Mueller Hinton II broth (MHB).
The overnight cultures were diluted 1:5 with fresh MHB, and mixed with molten soft
agar to achieve the density of ~108 CFU mL−1. From this mixture, 4-mL aliquots were
overlaid onto MHA base plates and allowed to completely solidify. After solidifying of
soft agar, 25 mm3 disks were overlaid on the plates and incubated at 37°C. The zones of
inhibition (ZOI) were measured after 30 h and reported as the radius from the edge of the
disk to the edge of the zone. Five replicates were carried out for each disk treatment and
bacterial strain with the mean and standard deviation reported.
4.3.8 Determination of Minimum Inhibitory Concentrations (MICs)
MICs of the PANDA disks were determined using a modified broth macrodilution
method. Briefly, overnight bacterial cultures in MHB were adjusted to ~105 CFU mL-1.
Various disks of different sizes (5-50 mm3) containing pCB at concentrations ranging
from 0.5 - 3 mg/mL of were added to 3 mL of bacterial solutions. The tubes then were
incubated at 37 °C at 200 rpm for 30 hours. Bacteria suspended in MHB served as a
positive control, while MHB without bacterial inoculum served as a negative control. The
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inoculated tubes were assessed by measuring optical density at 600 nm where OD < 0.05
considered negative for bacterial growth.
4.3.9 Kill kinetics via terminal dilution assays
To compare the rate of bacterial killing by 90% pCBA PANDA disks, the test
organisms were exposed to disks and change of viable bacteria was determined by a
modified terminal dilution method. The bacterial cultures were prepared and adjusted to
~105 CFU mL-1 as described above. The adjusted bacterial cultures (3 mL) were mixed
with (2 x 25 mm3) 90% pCBA PANDA disks. The inoculated tubes were incubated at
37°C with shaking (200 rpm) and bacterial populations were determined immediately
after the addition of disks (0 h), and at 2, 4, 8, 12, 24, and 30 hours of exposure. At each
time point, six 100 µL aliquots of the bacterial suspensions exposed to PANDAs were
transferred into 96-well microplates prefilled with 200 µL of MHB and serially diluted.
The inoculated microplates were incubated for 48 h at appropriate growth temperature,
after which the turbidity was measured with a BioTek Synergy 2 microplate reader. An
optical density at 600 nm of  0.05 was considered positive for bacterial growth.
Populations of viable bacteria were calculated from the final dilution (terminal dilution,
or TD), in which bacterial growth was observed using equation 1:
CFU
mL

=

10×3TD
1mL

(1)

Where TD is the terminal dilution factor obtained from microplate readings. The
calculated CFU/mL was taken as the average of the 6 replicates and the experiment was
repeated 3 times for each bacteria.
4.3.10 Evaluation of antifungal activity of PANDA disks
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The antifungal activity of 90% pCBA PANDA disks was tested against several
species of fungus using zone of inhibition method. The indicator microorganisms
included Candida albicans and Trichoderma harzianum. Fungus cultures were adjusted to
OD600 0.1 for C. albicans and 105 ppg/mL for T. harzianum. Mueller Hinton II agar
(MHA) plates have been spread with 100 L of fungus culture and 25 mm3 disks were
placed on the plates. Zone of inhibition was measured after 72 hours of incubation at
30°C.
4.3.11 Resistance Development Study
This study was done using a slight modification of a method reported by Haldar and
coworkers.153 MIC values for 90% pCBA PANDA disks were determined for P.
aeruginosa PAO-1 as described above. For the subsequent MIC determination, bacteria
solutions were made by using bacteria from sub-MIC concentrations of the disks (at
MIC/2). The bacteria solution was readjusted to ~105 via OD600 readings. Into 3 separate
vials, 3 mL of adjusted bacteria solution was added along with disks of various sizes.
After another 24 h incubation period, bacteria solutions again were made by using
bacteria from sub-MIC concentrations of the disks (at MIC/2). The resistance
development study was repeated twice, each with 20 total passages. The fold increase of
MIC was reported.
4.3.12 MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
cytotoxicity assay
The anti-proliferative activities of pCB and 90% pCBA PANDA degradation
products in 3% DMSO solution were determined following a standard literature
procedure.154 Briefly, 48 hours prior to treatment, KB cells (100,000 cells/mL, 100 μL)
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were seeded in a 96 well plate (Corning Inc.). Cells were treated with 50 μL of pCB and
50 μL of PANDA byproducts (media from 7 days incubation at pH 7.4). KB cells treated
with 3% DMSO solution served as control. Cell proliferation was determined via a
standard MTT assay (Vybrant MTT Cell Proliferation Assay Kit; Invitrogen). Cells were
incubated for 30 h before adding 10 µL of a 12 mM MTT reagent to each well. The cells
were further incubated for an additional 4 h, followed by removal of the media and
addition of 50 μL of DMSO. The absorbance was then determined utilizing a Biotek
Synergy2 MultiMode Microplate Reader, experiment was performed in quadruplicate.
4.4 Results and Discussion
Initially, we synthesized an acyclic diallyl p-chlorobenzaldehyde acetal (pCBA)
derived from pCB.

For proof-of-concept, pCB was selected from several possible

benzaldehyde derivatives with known antimicrobial activity.155-156 Benzylic aldehyde
derivatives are known to exert antimicrobial activity through a variety of mechanisms,
specifically, inhibition of H+-ATPase-mediated proton pumping activity, Schiff
base/thiazolidine formation with proteins/peptides, and membrane disruption.157-158 We
synthesized pCBA in acceptable yields via acid-catalyzed condensation of pCB with allyl
alcohol (1H/13C NMR Figure B.1-B.2). The antimicrobial activity of pCBA and pCB were
evaluated via a zone of inhibition (ZOI) assay with clinically isolated strains of E. coli
ATCC 43895 [serotype O157:H7], S. aureus RN6390, B. cenocepacia K56-2, and P.
aeruginosa PAO1 (Figure B.3). At the highest tested concentration (10 mg mL-1), pCBA
exhibited no apparent antimicrobial activity.

In contrast, pCB showed significant

inhibition at 0.5 mg mL-1 – results that indicate the acyclic acetal functions as a proantimicrobial compound with antimicrobial efficacy only upon hydrolysis to the aldehyde.
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UV-curable PANDA resins were then formulated with a photoinitiator,
pentaerythritol tetramercaptopropionate (PETMP), and varied concentrations of pCBA
relative to non-degradable 1,3,5-triallyl-1,3,5-triazine-2,4,6-trione (TTT) with 1:1
alkene:thiol mole stoichiometry (Figure 4.1). Following exploratory experiments, we
focused primarily on PANDAs synthesized from a 90:10 pCBA:TTT monomer feed as
proof-of-principle. This composition results in PANDA materials comprised of ~45 wt.%
pCBA. PANDAs were photopolymerized in the absence of solvent under a mediumpressure UV light (200 mW cm-2). Polymerization kinetics, investigated using real-time
FTIR, were rapid with near quantitative conversions (>95%) observed for both thiol and
alkene functional groups within 5 min (Figure 4.2a). The resulting PANDAs are
transparent, low modulus thermosets with a glass transition temperature (Tg) at 0.5 °C
(Figure 4.2b). Although not presented in detail here, the concentration of TTT can be used
to facilely tune the physical properties of the network (i.e., Tg, flexibility, degradation, etc.).
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Figure 4.2 Cure kinetics, thermomechanical properties, release kinetics and degradation
behavior of PANDAs. (a) Conversion kinetics for 90% pCBA resins cured at 200 mW
cm-2 UV light. (b) Representative thermomechanical plot of the 90% pCBA PANDA. (c)
Correlation between pCB released and incubation time at pH 6.0 and pH 7.4. (d) Timelapse macroscopic images of degradation of 90% pCBA disks submerged in PBS (pH
7.4) and (e) placed within a 90% humidity chamber under N2 at 25 °C. (Image contrast
enhanced for visibility). Error bars indicate the SD (n=5).
PANDA degradation and subsequent release of pCB were investigated at pH 7.4
and 6.0 by submerging sample disks (25 mm3) in phosphate buffer solution (PBS)
containing octanol to partition the aldehyde. Aliquots from the octanol phase were analyzed
via UV-vis spectroscopy to determine the concentration of pCB released over time. Figure
4.2c shows the pCB release profile at pH 7.4 and 6.0. At physiological pH, a 20 h lag time
was observed before pCB was slowly released from the polymer network, with 14% (1.07
mg mL-1) and 53% (4.19 mg mL-1) pCB release observed at 24 h and 48 h, respectively.
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Similar trends were observed at pH 6 with faster release kinetics, as expected, given the
rate of acetal hydrolysis is proportional to the H3O+ concentration.159 After 120 h, 72% and
80% pCB release was observed for pH 7.4 and pH 6.0, respectively. The photo series in
Figure 4.2d shows the sample disks immersed in PBS buffer solution (pH 7.4) as a function
of time. Shortly after immersion, the samples change from transparent to opaque white, but
retain their shape with receding dimensions over time. The observed release and
degradation behavior are consistent with a surface erosion process (typical of polyacetals),
and may be expected given that these materials are relatively hydrophobic (static water
contact angle ≈ 90°).160-161 The degradation behavior of these materials becomes
exceedingly more interesting when exposed to water vapor (rather than bulk immersion).
Figure 4.2e shows a photo series of PANDA disks subjected to a gentle flow of 90%
humidity within a scintillation vial (using N2 as a carrier for water vapor to avoid
acidification from CO2). Within 2 h, the PANDA disk hydrolyzed to a point where viscous
flow of the sample was observed. At 4 h, the degradation byproducts are shown flowing
down the supporting substrate. The rapid progression from an infinite polymer network to
viscous flow of low molecular weight degradation products is a consequence of the thiolene step polyaddition mechanism – a process that ensures most crosslink junctions contain
a degradable linkage and precludes the formation of high MW linear degradation products
found in chain growth networks.162-163 Notably, these observations point to a rapid bulk
degradation process and suggest a vast difference in water vapor permeability (under high
humidity) and liquid water permeability (under immersion) that may be exploited in the
synthetic design of humidity-triggered degradable materials. The increased permeability
towards water vapor is a phenomenon commonly observed in crosslinked
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poly(dimethylsiloxane) microfluidic chips which gradually lose water due to
evaporation.164 Furthermore, qualitative retarded degradation (Figure B.4). Experiments
are underway to quantify the degradation behavior under vapor conditions.

Figure 4.3 Antimicrobial activity and cytocompatibility assays. Error bars indicate the SD
(n=5). (a) Correlation between zone of inhibition and % pCBA in disk after 24 h
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incubation. (b) Kill kinetics of four bacteria in the presence of 90% pCBA PANDA via
terminal dilution assay. (c) Bacterial resistance study of the 90% pCBA PANDA and
tetracycline against P. aeruginosa. (d) Zone of inhibition diffusion assay of 0% and 90%
pCBA PANDAs against C. albicans and T. harzianum. (e) Split plate diffusion assay of
90% pCBA PANDA disks against C. albicans after 30 days. (f) Cell viability assay for
control (DMSO), pCB, and degraded 90% pCBA PANDA.

The synthetic design of PANDAs is motivated by the potential use of these
materials in antimicrobial/ antifungal applications. The antimicrobial activity of PANDAs
was initially evaluated via a ZOI assay with clinically isolated strains of E. coli ATCC
43895 [serotype O157:H7], S. aureus RN6390, B. cenocepacia K56-2, and P. aeruginosa
PAO1. As shown in Figure 4.3a, PANDAs containing 0% pCBA showed no ZOI, as
expected, and serve as a control for the assay. PANDAs containing >60% pCBA exhibited
ZOIs, with larger ZOIs observed for all bacteria with increasing concentration of pCBA
(relative to TTT) in the polymer network. The antimicrobial efficacy of the 90% pCBA
PANDA material was further investigated using a terminal dilution assay to quantify kill
kinetics. Two 25 mm3 90% pCBA PANDA disks (3.6 mg mL-1 pCBA released within 24
h) exhibited more than a 5 log reduction in bacteria count in < 12 h against E. coli, S.
aureus, and other pathogens (Figure 4.3b), which translates into kill efficiencies of
>99.999%. In interest of developing strategies and materials to mitigate the development
of antimicrobial resistance, we evaluated the potential emergence of bacterial resistance of
P. aeruginosa against pCBA-based PANDAs using a serial passage mutagenesis assay.
For comparison, the same assay was performed using tetracycline. Figure 4.3c shows the
inability of P. aeruginosa to develop resistance toward pCB released from PANDA disks
after 20 serial passages as indicated by the absence of an increase in the MIC (25 mm3 disk
≈ 1.3 mg mL-1 pCB released within 24 h). We note that the concentration of pCB released
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from the disk after 24 h is comparable to the small molecule MIC at 1.25 mg mL-1. In
contrast, the MIC value for tetracycline increased after only two passages, with a 10-fold
increase in MIC after 20 passages. The results suggest that P. aeruginosa has less
propensity to develop resistance against the pCB released from pCBA-based PANDAs,
which highlights the potential of PANDAs for use as part of a broader strategy to slow or
mitigate the development of antimicrobial resistance.
To further probe the broad-spectrum activity of pCBA PANDAs, we performed
zone of inhibition experiments against two opportunistic pathogenic fungi (C. albicans and
T. harzianum).165-166 Placement of a 25 mm3 90% pCBA PANDA disk resulted in complete
inhibition of both fungi whereas the same size disks containing 0% pCBA exhibited no
measurable antimicrobial activity (Figure 4.3d). Borrowing from the known inhibitory
activity of volatile EOs, we exploited the inherent volatility of pCB to inhibit C. albicans
– a pathogenic fungus responsible for up to 65% of all candidiasis cases in humans – via
a split plate inhibition volatility assay.166 As shown in Figure 4.3e, 25 mm3 90% pCBA
PANDA disks were placed on one side of a 9 cm split Petri dish with C. albicans plated on
agar on the opposite side. The dish was sealed and incubated for 30 days. In the absence of
PANDA disks (control), zero inhibition was observed. Partial inhibition was observed with
one disk, while the growth of C. albicans was completely inhibited by two disks for up to
30 days. These experiments exploit the humidity-triggered degradation and volatility of
pCB for non-contact control of fungus. Finally, KB cells (a type of HeLa cells), derived
from a glandular cancer of the cervix were used as a model cell line for cytotoxicity. 167
Incubation of the KB cells with a degraded 90% pCBA disk (e.g. media containing
PANDA degradation products after 7 days at pH 7.4, equivalent to 2.5 mg mL-1 pCB) and
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small molecule pCB at the same concentration showed no significant toxicity (>90%
viability) to KB cells (Figure 4.3f).
In summary, we have demonstrated the proof-of-principle for pro-antimicrobial
networks via degradable acetals. PANDAs undergo degradation under mild conditions to
release pCB – a small molecule active that serves as a potent antimicrobial agent against a
broad spectrum of microbes. The humidity triggered degradation and volatile release of
pCB was exploited to inhibit the growth of C. albicans without the need for direct contact.
Importantly, the broad spectrum antimicrobial efficacy was achieved with minimal
cytotoxicity towards KB HeLa cells. Solvent-free, room temperature photopolymerization
provides a rapid, one-pot approach to crosslinked polyactives with excellent potential for
advanced processing techniques, including 3D printing. The PANDA approach presented
here is readily applicable to other bioactive aldehydes pointing to the potential use of these
materials within pharmaceutical, biomedical, and agricultural industries.
4.5 Conclusions
We have reported that PANDAs, building upon linear “polyactives”, represent a new
paradigm for sequestration and triggered release of volatile, bioactive aldehydes. As proofof-concept, we showed that PANDAs derived from diallyl p-chlorobenzaldehyde acetal
and pentaerythritol tetramercaptopropionate degrade and release p-chlorobenzaldehyde
(pCB) as an antibacterial and antifungal agent under mild conditions (pH 7.4/high
humidity). Notably, the thiol-ene step polyaddition process ensured that most crosslink
junctions contain a degradable acetal linkage enabling rapid progression from an infinite
polymer network to low molecular weight degradation products.

We showed that

PANDAs enable facile access to materials sequestering up to 50 wt% pCB with tunable
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release profiles, potent antimicrobial activity against Gram positive and Gram negative
bacteria without triggering antimicrobial resistance, and minimal cytotoxicity. We also
demonstrated the utility of PANDA materials by exploiting humidity-triggered degradation
and volatile release of pCB from the polymer network for vapor-phase inhibition of
Candida albicans – where a 50 µL PANDA disk provided 30 days of inhibition. To our
knowledge, this represents a first example of the pro-antimicrobial approach manifested in the form
of crosslinked polymer networks exhibiting broad spectrum antimicrobial activity. Significantly,

the PANDA approach is readily applicable to sequestration and release of other bioactive
aldehydes and is translatable to various material geometries (e.g., particles, thin films,
printable scaffolds) pointing to potential use of these materials within pharmaceutical,
biomedical, and agricultural applications.
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CHAPTER V – A BIO-BASED PRO-ANTIMICROBIAL POLYMER NETWORK VIA
DEGRADABLE ACETAL LINKAGES
5.1 Abstract
The synthesis of a fully degradable, bio-based, sustained release, proantimicrobial polymer network comprised of degradable acetals (PANDA) is reported.
The active antimicrobial agent – p-anisaldehyde (pA) (an extract from star anise) – was
converted into a UV curable acetal containing pro-antimicrobial monomer and
subsequently photopolymerized into a homogenous thiol-ene network. Under neutral to
acidic conditions (pH < 8), the PANDAs undergo surface erosion and exhibit sustained
release of pA over 38 days. The release of pA from PANDAs was shown to be effective
against both bacterial and fungal pathogens. From a combination of confocal microscopy
and transmission electron microscopy, we observed that the released pA disrupts the cell
membrane. Additionally, we demonstrated that PANDAs have minimal cytotoxicity
towards both epithelial cells and macrophages. Although a model platform, these results
point to promising pathways for the design of fully degradable sustained-release
antimicrobial systems with potential applications in agriculture, pharmaceuticals,
cosmetics, household/personal care, and food industries.
5.2 Introduction
With the increasing prevalence of antimicrobial resistance (AMR), opportunistic
pathogens pose a significant global crisis. Compounding the issue, over 23.5 million
immunocompromised patients (i.e. patients with rheumatoid arthritis, HIV, organ
transplants, etc.) are prescribed immunosuppressants, making them more prone to both
fungal and bacterial infections 168. For instance, the fungus Histoplasma capsulatum
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aggressively infects immunocompromised patients with over 500,000 cases annually in
the United States, 300,000 of which are HIV-related infections resulting in 10,000 deaths
per year 169. Additionally, exposure to other common pathogens such as Pseudomonas
aeruginosa, Escherichia coli, Salmonella Typhi, and Staphylococcus aureus can escalate
into life threating infections resulting in sepsis and death 170-171. To combat AMR, new
antimicrobial strategies with low propensity to trigger resistance have been developed
including quorum sensing inhibitors 172, synergistic pairing to induce sensitivity 173-174,
antibiotic adjuvants 175, antibiotic cycling 176, and multimodal antibiotics 177-178. Of the
aforementioned methods, essential oils (EOs) – a unique class of naturally occurring,
plant-derived extracts – hold promise in eradicating resistant microbial populations via
the multimodal approach. EOs exhibit broad spectrum antimicrobial activity by
interfering with membrane integrity, ATP synthesis, protein stability, and quorum
sensing pathways 3, 16. Despite positive results, the use of EOs is still restricted due to
their limited water solubility, high volatility, and chemical instability 17. Many
approaches have been reported to sequester EO derivatives within polymeric materials;
however, these strategies often utilize slow or non-degradable linkages which slowly
release or permanently entrap EOs.
Poly(actives), or polymeric pro-drugs that rely on degradable linkages for the
release of therapeutic agents, can improve chemical stability, enable tunable release
profiles, and reduce volatility 24. Multiple linear poly(actives) have been reported
including poly(esters) 179-180, poly(anhydride-esters) 138, 181-187, poly(anhydride-amides)
188

, poly(carbonate-amides) 189, poly(carbonate esters) 190, poly(ketals) 191, and

poly(oxalate-acetals) 25. While linear poly(actives) successfully entrap drugs and allow
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for tunable release profiles, crosslinked poly(actives) represent a relatively unexplored
class of degradable drug-releasing materials where opportunities for greater control over
degradation profiles, thermomechanical properties, and sample geometry (particles, thin
films, or coatings) are available. Recently, crosslinked poly(actives) including
poly(esters) 144, 192-193, poly(-amino esters) 194, and poly(acetals) 68 have utilized
degradation rates, crosslink density, and hydropathy as mechanisms to control the release
of actives. Of the degradable linkages available, both acetals and ketals have gained
recent attention because of their charge-neutral and potentially nontoxic byproducts
(alcohols and ketones/aldehydes) upon cleavage 195.
We have recently demonstrated the sequestration of p-chlorobenzaldehyde within
a pro-antimicrobial network via degradable acetals (PANDA) 68. While pchlorobenzaldehyde is a relatively potent antimicrobial drug, we wanted to shift focus
away from oil derived compounds and towards bio-based aldehydes found in nature to
offer a fully degradable antimicrobial system based on essential oils. In this work, we
turned towards p-anisaldehyde (pA), an extract from star anise (Pimpinella anisum)
seeds, to fabricate a new class of antimicrobial PANDAs. We demonstrate that
incorporation and subsequent release of pA from a PANDA exhibits potent antimicrobial
activity against a variety of clinically relevant pathogens with minimal cytotoxicity.
5.3 Experimental
5.3.1 Materials
The chemicals p-anisaldehyde (pA), trimethylol propane diallyl ether, 2-hydroxy2-methylpropiophenone (Darocur 1173), trimethylsilyl trifluoromethanesulfonate
(TMSOTf), dichloromethane (DCM), allyloxytrimethylsilane, pyridine, sodium
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bicarbonate, diethyl ether, magnesium sulfate (MgSO4), dextrose, 2,3,5,6tetrachloronitrobenzene, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), hexane, 0.5 M Tris-HCl in H2O, acetonitrile-d3, Aqua Dead Cell Stain™,
LIVE/DEAD BacLight Bacterial Viability Kit staining kit, BacLight RedoxSensor CTC
Vitality Kit and ethyl acetate were acquired from Thermo Fisher Scientific.
Pentaerythritol tetra(3-mercaptopropionate) (PETMP) was provided by Bruno Bock.
Difco Agar, yeast extract, Bacto Tryptone, Mueller Hinton broth and agar, were from
Becton, Dickinson and Company. Ham's F-12 and trypsin-EDTA were obtained from
GIBCO. Hemin chloride (type II), protoporphyrin IX, histidine (free base), proline, 37%
formaldehyde in H2O, dimethyl sulfoxide (DMSO), fluconazole, fetal bovine serum
(FBS), Dulbecco's Modified Eagle's Medium (DMEM) and N-2-hydroxyethylpiperazineN'-2-ethanesulfonic acid (HEPES) was purchased from Sigma Aldrich. All the materials
were obtained at the highest purity available and used without further purification unless
otherwise specified.
5.3.2 Characterization Methods.
A Bruker Ascend 600 MHz (TopSpin 3.5) spectrometer was used to record 1H/13C
NMR spectra with either chloroform-d or acetonitrile-d3. High resolution mass
spectroscopy (HRMS) was performed with positive electrospray ionization on a Bruker
12 Tesla APEX-Qe FTICR-MS with an Apollo II ion source. Dynamic mechanical
analysis (DMA) was performed using a TA Instruments Q800 dynamic mechanical
analyzer in tension mode equipped with a gas cooling accessory. Samples were clamped,
evaluated at a strain of 1 %, and heated from -80 °C to 80 °C at a ramp rate of 3 °C min-1.
Kinetic data was obtained using real-time FTIR (RT-FTIR) spectroscopy by determining
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the conversions of the thiol and ene functional groups. The RT-FTIR studies were
conducted using a Nicolet 8700 FTIR spectrometer with a KBr beam splitter and a
MCT/A detector with a 320–500 nm filtered ultraviolet light source. Each sample was
exposed to a UV light with an intensity of 400 mW cm-2. Series scans were recorded,
where spectra were taken approximately 2 scan s-1 with a resolution of 4 cm-1. Thiol
conversion was monitored via integration of the SH peak between 2500-2620 cm-1 while
the conversion of the alkene was monitored between 3050-3125 cm-1. Optical density
(OD) and fluorescence readings were performed in a BioTek Synergy 2 programmable
microplate reader (BioTek Instruments).
5.3.3 Synthesis of p-anisaldehyde diallylacetal (pAA)
The synthesis of pAA was done using a slightly modified procedure from Noyori
and coworkers 196. To a flame dried 250 mL round bottom equipped with a stirbar,
TMSOTf (200 µL, 1.1 mmol) was added along with 30 mL dry DCM under nitrogen at 84 °C. While maintaining the same temperature, a mixture of allyloxytrimethylsilane (37
mL, 208 mmol) and pA (12 g, 88 mmol) in 25 mL of dry DCM was added dropwise into
the round bottom. The reaction turned yellow and stirred for 3 h. After, the reaction was
warmed to -30 °C and stirred for 1 h (reaction turned red). The deep red mixture was then
quenched with the addition of pyridine (15 mL, 74.5 mmol) and poured into 100 mL of
saturated sodium bicarbonate prior to extraction with (3 x 100 mL) of diethyl ether. The
organic layer was dried over anhydrous MgSO4, then the excess solvent was removed
under reduced pressure. The yellow oil was then purified via column chromatography
using a mixture of hexane: ethyl acetate (9:1) and yielded a clear oil (13.6 g, 65.9 %
yield). 1H NMR (CDCl3) δ 7.45 (dd), 6.93 (dd), 5.97 (m), 5.62 (s), 5.35 (dd), 5.17 (dd),
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4.07 (d), 3.82 (s). 13C NMR (CDCl3) δ 159.66, 134.16, 130.68, 127.97, 116.67, 113.52,
100.29, 66.00, and 55.22. HRMS (ESI+) m/z calculated for C14H18O3 [M+Na]+
257.114816; Found 257.114817.
5.3.4 General preparation of PANDA disks
The PANDA disks were prepared by adding PETMP and pAA at 1:1 ratio of SH:alkene,
along with 4 wt.% of Darocur 1173. The mixtures were well mixed and 25 μL of the
monomer formulations were aliquoted onto a glass slide and covered with another glass
slide spaced with Teflon spacers (0.76 ± 0.02 mm in thickness). The samples were then
cured using an Omnicure S1000-1B with a 100W mercury lamp (λmax = 365 nm, 320–
500 nm filter) at an intensity of 400 mW cm−2 for 40 seconds. Control disks were
prepared following the same procedure by using PETMP and trimethylol propane diallyl
ether at 1:1 ratio of SH to alkene with addition of 4 wt.% of Darocur 1173..
5.3.5 Degradation of PANDAs
The hydrolysis of PANDA disks was analyzed via 1H NMR under a pH 7.4 TrisHCl buffered water:acetonitrile-d3 solution. First 2,3,5,6-tetrachloronitrobenzene (internal
standard) was weighed into a vial along with 500 µL of acetonitrile-d3. Then 125 µL of
100 mM Tris-HCl in deionized water was added and mixed. A 5 mm3 disk and 500 µL of
the acetonitrile:buffer solution was added to an NMR tube and sealed. Three replicates
were prepared for each data point (with mean and standard deviation reported) and NMR
spectra were taken over 38 days. To calculate the concentration released of different sized
PANDA disks (5-100 mm3), the grams of pA released (at 24 and 48 h from a 5 mm3 disk)
were multiplied by a factor to equal the desired PANDA disk size (e.g. x10 for a 50 mm3
disk) and divided by the total volume the disk was placed into. Since the thickness of the
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PANDA disks does not change, this assumption is valid, however the degradation profile
in the presence of microbes may not be the same as pH 7.4 PBS, yet remains our best
estimate.
5.3.6 Evaluation of antibacterial activity of PANDAs
5.3.6.1 Zone of inhibition (ZOI) assay
The antimicrobial activity of PANDA disks was tested against several species of
bacteria via the zone of inhibition method. The indicator microorganisms included
Escherichia coli ATCC 43895 (serotype O157:H7), Staphylococcus aureus RN6390,
Salmonella enterica serovar Typhi ATCC 6539 (S. Typhi), and Pseudomonas aeruginosa
PAO1. The testing was done on Mueller Hinton II agar (MHA) plates that have been
overlaid with soft agar seeded with individual bacterial strains. The soft agar contained
(per liter): 10 g of Bacto Tryptone, 6 g of Difco agar, and 8 g of sodium chloride. To
create an overlay, the indicator organisms were grown overnight at 37 °C in Mueller
Hinton II broth (MHB). The overnight cultures were diluted 1:5 with fresh MHB, and
mixed with molten soft agar to achieve a ~108 CFU mL−1 density. From this mixture, 4
mL aliquots were overlaid onto MHA base plates and allowed to completely solidify.
After solidification of the soft agar, 50 mm3 disks were overlaid on the plates and
incubated at 37 °C. The zones of inhibition (ZOI) were measured after 24 h and reported
as the distance from the edge of the disk to the edge of the zone. Three replicates were
carried out for each disk/bacterial strain. with the mean and standard deviation reported
(experiment was repeated twice).
5.3.6.2 Minimum inhibitory assay
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Minimum size of PANDA disks required to inhibit bacterial growth were
determined using a modified broth macrodilution method. Briefly, overnight bacterial
cultures in MHB were adjusted to ~105 CFU mL-1. PANDA disks of different sizes (5100 mm3) were added to 4 mL of bacterial solutions. The tubes were then incubated at 37
°C and shaken at 200 rpm for 24 h. Bacteria suspended in MHB served as a positive
control, while MHB without bacterial inoculum served as a negative control. The
inoculated tubes were assessed by measuring optical density at 600 nm after 24 h where
OD < 0.05 considered negative for bacterial growth. Three replicates were carried out for
each disk size and bacterial strain. with the mean and standard deviation reported
(experiment repeated twice).
5.3.6.3 Kill kinetics via track dilution assays
To compare the rate of bacterial killing by PANDA disks, the test organisms were
exposed to 100 mm3 PANDA disk and the number of viable bacteria was determined by a
modified kinetic track dilution method 197. Individual disks were submerged in 4 mL
aliquots of bacterial cultures adjusted to ~105 CFU mL-1 as described above and
incubated at 37 °C with shaking (200 rpm). Bacterial populations were determined
immediately after the addition of disks (0 h), and at 4, 8, 16, 24, 30, and 48 h of exposure.
For the track-dilution technique, Falcon 15-mm square plates with 13-mm grids (Becton
Dickinson Labware) were used. At each time point, six 20 µL aliquots of the bacterial
suspensions exposed to PANDAs were transferred into 96-well microplates prefilled with
200 µL of MHB and serially diluted 1 to 10 to reach a final dilution of 10-8. From
inoculated samples, 10 µL were spotted on the agar surface along one side of the square
plate using a multichannel micropipette. The plate was tipped onto its side (at a 45°–90°
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angle), to allow inoculum to migrate in parallel tracks across the agar and to dry for 1
min. The plate was then inverted and incubated for 24 h at 37 °C prior to colony
counting. Bacteria suspended in 4 mL MHB served as a positive control, while MHB
without bacterial inoculum served as a negative control. Three replicates were carried out
for each time point and bacterial strain with the mean and standard deviation reported
(experiment repeated twice).
5.3.6.4 Determination of respiratory activity
A BacLight RedoxSensor CTC Vitality Kit was used to evaluate respiratory
activity of bacteria (adjusted to ~105 CFU mL-1) exposed to either PANDA disks or
control disks (100 mm3) after a 24 h incubation at 37°C at 200 rpm. According to the
manufacturer’s protocol, 5-cyano-2,3-ditolyl tetrazolium chloride (CTC) (15 mg) was
dissolved in 1 mL of sterile deionized water. Next, 180 µL of each sample was mixed
with 20 µL of the CTC solution in a Corning™ 96-well solid black microplate and
incubated at 37 °C for 30 min prior to reading with a BioTek reader equipped with a
monochromator at 450 nm excitation and 630 nm emission.
5.3.6.5 Assessment of cell membrane integrity
Bacterial cell membrane integrity was evaluated using a LIVE/DEAD BacLight
Bacterial Viability Kit. A 4 mL of ~105 CFU mL-1 P. aeruginosa was prepared and
exposed to a 100 mm3 PANDA disk, prior to incubation at 37 °C with constant shaking
(200 rpm). From each inoculated sample, 100 µL aliquots of the bacteria from the
PANDA treatment were transferred into a Corning™ 96-well solid black microplate, and
mixed with 100 µL of the LIVE/ DEAD BacLight staining reagent. The samples were
taken at 0 and 30 h and incubated in the dark for 15 min. The fluorescence was measured
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using a 485/20 nm excitation filter (for both SYTO9 and propidium iodide) and two
separate emission filters: 528/20 nm (SYTO9 emission wavelength) and a 620/40 nm (PI
emission wavelength). For confocal imaging, 5 µL of the stained samples were cast onto
separate microscope slides. Each sample was assayed in triplicate, and the experiment
was repeated twice. From the inoculated sample, transmission electron micrographs were
taken with a Zeiss 900 electron microscope operating at 50 kV and outfitted with a Model
785 Erlangshen ES1000 WCCD camera (Gatan). Samples were applied to 200 mesh
copper grids (3.05 mm, 200 lines per inch square mesh, Electron Microscopy Sciences)
coated with Formvar (5% polyvinyl formal resin).
5.3.7 Determination of antifungal activity
5.3.7.1 Zone of inhibition assay
The wild-type Histoplasma capsulatum G217B (ATCC 26032) strain was used in
this study. Liquid H. capsulatum yeast cultures were grown to mid-log (OD600 ~1.4-1.9)
in Histoplasma macrophage medium (HMM) 198 and enumerated using a hemocytometer
(Incyto C-Chip). Once quantified, 1.0 x 107 cells were spread in triplicate onto prewarmed solid HMM plates and allowed to dry for 1 h before PANDA disks (50 mm3)
were overlaid in the center of each plate. After 4 days of incubation at 37 °C in 5% CO2 /
95% room air, images were captured using a DinoLite microscope camera and zones of
inhibition were measured using the DinoLite software. For a negative control, a control
disk was added, whereas, the positive control contained 4 mg fluconazole. Three
biological replicates were used to calculate mean and standard deviation (experiment
repeated twice).
5.3.7.2 Determination of minimum inhibitory concentration (MIC)
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Four-day-old H. capsulatum yeast cultures were diluted 1:5 and grown overnight
at 37 °C in 5% CO2 / 95% room air with shaking (200 rpm). Cells were then diluted with
pre-aerated, pre-warmed HMM to a final OD600 of 0.1. Various sizes of PANDA disks
(0-45 mm3) were added to 50 mL aliquots of the diluted yeasts as described above. The
cultures were then incubated for a total of 7 days. Every 24 h, 1 mL aliquots of each
culture were transferred to disposable plastic cuvettes and OD600 was measured using a
BioTek reader. After 7 days, a growth curve of OD600 vs. time was generated to
determine MICs. The experiment was repeated twice.
5.3.7.3 Fungal viability
For LIVE/DEAD staining of H. capsulatum yeast-phase cells, 1 mL aliquots of a
mid-log phase culture of H. capsulatum challenged with either 45 mm3 control or
PANDA disks was centrifuged at 1000 × g for 5 min, washed once with PBS, and resuspended in PBS. Next, cells were enumerated via hemocytometry and diluted to 1 x
106 cells per mL. At this point Aqua Dead Cell Stain™ was added to the cell suspension
in a final dilution of 1:1000 and incubated for 30 min at room temperature in the dark.
Once labelled, the cells were washed with PBS and fixed with 37% formaldehyde for 15
min at room temperature. Flow cytometry was performed on a BD Accuri C6 Flow
Cytometer using an excitation wavelength of 405 nm with emission capture at ~525 nm.
A gate was then applied and viability assessed by analyzing the shift in fluorescent
intensity. To qualitatively assess fungal viability, the same labelled cells were analyzed
on a Zeiss LSM 510 Meta confocal microscope at 40x magnification using both
differential interference contrast and 405 nm laser excitation.
5.3.7.4 Direct contact mammalian cell viability
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To assess the effects of the PANDAs directly on host cells, a direct contact assay
based on ISO 10993-5 with MTT was used to quantify viability of RAW 264.7 murine
macrophages and VERO epithelial cells (isolated from kidney) after the addition of either
control (1.5 mm3) or PANDA disks (0.5, 1.0, and 1.5 mm3) 199. Cells with no additional
supplementations were used as a control. Six replicates were measured to calculate
percent survival and standard deviation. The MTT assay was carried out per the
manufacturer’s protocol (Thermo Fisher) with modifications to adapt the assay from the
standard 96-well plate to a 24-well cell culture plate. Both RAW 264.7 and VERO cell
lines were maintained in 20 mL DMEM supplemented with 10% FBS, 50 µg mL-1
ampicillin, 4.5 mg mL-1 glucose, 584 µg mL-1 L-glutamine, and 100 µg mL-1
streptomycin in T-150 culture flasks (Sigma). Cells were incubated at 37 °C in 5% CO2.
Briefly, cells were grown to confluence and detached from the culture flask with trypsinEDTA and centrifuged briefly at 200 × g for 5 min. They were then re-suspended in 1 mL
DMEM and enumerated using a hemocytometer. The cells were diluted to 5.0 x 104 cells
mL-1 and 1 mL aliquots were added to each well of a 24-well cell culture plate (Sigma).
Once the culture reached subconfluency (~80% confluency) in the 24-well plate, 1.5 mm3
disks were overlayed on the cells and allowed to incubate for 24 h at 37 °C in 5% CO2.
After the incubation, all media were removed from the wells and replaced with 500 µL of
Dulbecco’s phosphate-buffered saline (DPBS), pH 7.5. 50 µL of 12 mM MTT was then
added to each well and incubated at 37 °C for 2 h. After labelling the cultures with MTT,
all but 250 µL of DPBS/MTT mixture was removed from the wells. To solubilize the
MTT dye, 500 µL of DMSO was added to each well and mixed thoroughly before
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incubating at 37°C for 10 min. Lastly, each 24-well plate was mixed and absorbance was
read at 540 nm. Experiment was repeated twice.
5.3.7.5 Statistical Analysis
All measurements were made in triplicate unless otherwise stated and each
experiment was performed on at least two separate occasions; the results are expressed as
the average of the parallel assays with error bars representing a standard deviation from
the mean.”
5.4 Results and Discussion
5.4.1 Monomer synthesis and PANDA fabrication/properties
As shown in Scheme 5.1A, the acyclic diallyl p-anisaldehyde acetal (pAA) was synthesized
in modest yields (66% after column) through Noyori’s acetal forming procedure by the
reaction of allyloxytrimethylsilane with pA in the presence of TMSOTf ( 1H NMR, Fig.
5.1A) 196. To assess the pro-antimicrobial nature of pAA, 10 µL of pure pAA and pA were
placed on plates overlayed with S. Typhi (Scheme 5.1A). After 24 h of incubation, pAA
showed no apparent zone of inhibition indicating no antimicrobial activity. In contrast, pA
showed a 1 cm zone of inhibition indicating that pAA functions as a pro-antimicrobial
compound only exhibiting antimicrobial activity upon hydrolysis back to pA.
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Scheme 5.1 Overview of monomer synthesis and PANDA fabrication. (A) Synthesis of
pro-antimicrobial pAA from antimicrobial pA. Antimicrobial properties of pAA/pA are
indicated by a zone of inhibition assay against S. Typhi. (B) Monomers used to
synthesize the PANDAs via thiol-ene photopolymerization and acid mediated
transformation of pAA to pA. (C) Schematic depiction of PANDA degradation
mechanism.
To fabricate PANDAs, pentaerythritol tetrakis(3-mercaptopropionate) (PETMP),
photoinitiator and pAA were copolymerized with 1:1 alkene/thiol mole stoichiometry via
radically mediated step-growth thiol-ene photopolymerization (Scheme 5.1B). The
fabricated PANDAs are comprised of 47 wt.% pAA which corresponds to 27 wt.% pA
loading. The polymerization kinetics are rapid and exhibit nearly quantitative monomer
conversion (>95%, Fig. 5.1B) for both thiol and alkene functional groups within seconds
under a medium pressure UV light (400 mW cm−2). The step-growth polymerization
ensures that each crosslink junction contains a hydrolytically cleavable acetal linkage for
the release of pA from the network (Scheme 5.1C). Additionally, the resulting PANDAs
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possess a narrow tan  (indicative of a homogenous network), a glass transition temperature
of -0.5 °C (Fig. 5.1C), and are optically transparent – typical of thiol-ene materials 33.

Figure 5.1 Monomer structure, cure kinetics, and final network properties. (A) 1H NMR
spectra of pAA. (B) Real-time FT-IR of SH and ene conversion during
photopolymerization. (C) Dynamic mechanical analysis of the resulting PANDA.
5.4.2 PANDA release kinetics
The release kinetics of pA from the PANDAs were monitored via 1H NMR spectroscopy
over 38 days at pH 7.4 by submerging disks in buffered solutions in acetonitrile-d3 within
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sealed NMR tubes. An internal standard, 2,3,5,6-tetrachloronitrobenzene ( = 7.75 ppm),
was added to the buffered solution and integrated relative to the benzylic aldehyde proton
( = 9.85 ppm) to determine the concentration of pA over time (Fig. 5.2A). Figure 5.2B
shows the release profile of pA from the integrated 1H NMR results. At physiological pH,
no burst release was observed and 90% pA was released after 38 days. The release profile
was then fit to the cylindrical Hopfenberg model 200 described as:
𝑀𝑡
𝑘0 𝑡 2
= 1 − [1 −
]
𝑀∞
𝐶0 𝑎
where, 𝑀𝑡 is the concentration of released pA at time t, 𝑀∞ is the theoretical maximum of
pA released, 𝑘0 is the erosion rate constant, 𝐶0 is the initial concentration of drug in the
matrix, and a is the initial radius of the cylinder. From the Hopfenberg model, the half-life
was determined to be 14.9 days and the fit was in good agreement with the release data as
indicated by an r2 value of 0.989. To verify the surface erosion of the PANDAs, control
(PETMP and trimethylolpropane diallyl ether) and PANDA disks were fabricated,
immediately submerged in a 1N aqueous HCl solution, and imaged over time. Within 1 h,
significant surface erosion was visually observed as noted by the degradation front
highlighted by the green arrows in Figure 5.2C. Due to the immiscibility of the degradation
byproducts in water, the solid disk gradually transitions to an oil-like residue within 3 h.
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Figure 5.2 Degradation of PANDAs. (A) 1H NMR degradation kinetics of PANDA at pH
7.4. (B) Cumulative release of pA from PANDA subjected to pH 7.4. (C) Kinetic optical
microscopy images of a PANDA disk submerged in 1 N HCl. Green arrows indicate
remaining PANDA disk. (D) Calculated cumulative area from 1N HCl degradation
kinetics determined by imageJ analysis.
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A plot of the remaining disk area at time t (At) relative to the initial area (A) was
plotted overtime and then fit by the Hopfenberg model, where 𝑀𝑡 /𝑀∞ were replaced by
𝐴𝑡 /𝐴∞ (Fig. 5.2D). In comparison to the degradation at pH 7.4, the degradation at pH 0.1
was 380x faster (half-life = 0.04 days), indicating that PANDA degradation is acid
sensitive. While small molecule model studies show that acetal degradation is generally 10
times faster with each unit of pH decrease201, Liu et al. reported that crosslinked acetal
network degradation follows small molecule degradation kinetics qualitatively195.
Moreover, Garripelli and coworkers showed that acetal-based material degradation does
not follow first order kinetics relative to the hydronium ion concentration202. The
differences between network and small molecule degradation are likely attributed to
differences in accessibility of the acid to each acetal as well as the hydropathy of the
crosslinked network.
5.4.3 PANDA antibacterial activity
5.4.3.1 Bacterial inhibitory assays
The use of pA was motivated by its potent activity exhibited in screening experiments
against pathogenic bacteria. The antimicrobial activity of 50 mm3 PANDAs and control
disks was initially evaluated via a ZOI assay with clinically isolated strains: S. aureus
RN6390 and P. aeruginosa PAO1, and foodborne pathogens: E. coli ATCC 43895
(serotype O157:H7) and S. Typhi ATCC 6539 (Fig. 5.3A). In all cases, the control disks
showed no inherent antimicrobial activity towards any bacteria, whereas zones of
inhibition (>1 cm) were present for the PANDA disks. The ZOI assay showed that the
order of antimicrobial inhibition was S. Typhi > S. aureus > E. coli O157:H7 > P.
aeruginosa.
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Figure 5.3 Antibacterial activity of PANDAs. (A) ZOI of PANDA and control disks.
Plotted data points represent individual measurements. (B) Minimum inhibition assay of
different sized PANDA disks. (C) Time-dependent killing of pathogens by 100 mm3
PANDA disks. Data are representative of 2 independent experiments ± s.d.
To determine the PANDA disk size required to inhibit bacterial growth, a minimum
inhibitory disk size assay was performed with exponentially grown bacteria (105 CFU mL1

in 4 mL media) challenged with PANDA disks (0-100 mm3). As shown in Figure 5.3b,

an increase in disk size correlates with an increase in bacterial inhibition with a 100 mm3
PANDA disk [910 µg mL-1 released after 24 h (determined from Fig. 5.2B)] completely
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inhibiting the growth of all bacteria. The trend in bacterial susceptibility from the ZOI
assay was also observed in the minimum inhibition assay with E. coli O157:H7 and P.
aeruginosa requiring the largest PANDA disk (100 mm3), while S. Typhi and S. aureus
were inhibited by a 50 mm3 PANDA disk [455 µg mL-1 released after 24 h (determined
from Fig. 5.2B). These determined MICs are in good agreement with other inhibition
studies involving pA 8.
5.4.3.2 Determination of bacteriostatic/bactericidal activity of PANDA disks
To examine the bactericidal activity of 100 mm3 PANDA disks, the number of viable
bacteria was quantified via a kinetic track dilution assay at 0, 4, 8, 16, 24, 30, and 48 h
(Fig. 5.3C). The PANDA disk (1085 µg mL-1 pA released within 48 h) exhibited
bactericidal activity with a >4 log reduction in bacteria count (>99.99% elimination)
against P. aeruginosa, E. coli, and S. Typhi. However, the concentration of gram-positive
S. aureus remained constant at 105 CFU mL-1, indicating a bacteriostatic effect. Our results
are

in

agreement

with

previous

studies

which

have

shown

that

the

bactericidal/bacteriostatic activity is dependent on both EO concentration and bacterial
species 203-204.
5.4.3.3 Evaluation of bacterial respiratory activity and membrane integrity
To investigate the antibacterial efficacy of PANDA disks (100 mm 3), a series of
physiological assays along with micrographs were performed. The fluorogenic probe, 5cyano-2,3-ditolyl tetrazolium chloride (CTC) was used to measure bacterial respiratory
activity. Bacteria capable of respiration reduce CTC into CTC-formazan (CTF), an
insoluble, fluorescent product that can be quantified via fluorescence readings. As shown
in Figure 5.4A, in comparison to the control disks, bacteria treated with PANDAs showed
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a 90-95% loss of fluorescence indicating a significant decrease in respiratory activity.
Interestingly, with S. aureus, PANDAs had a bacteriostatic effect and the population
remained unchanged despite the significant decrease in metabolic activity. The different
response of bacteria to pA is not unprecedented as some antibiotics can act as both
bactericidal or bacteriostatic agents 205. Lobritz et al. 205 attributed the differences between
the bactericidal or bacteriostatic modes of actions to the interference with cellular
respiration. Bactericidal antibiotics cause an acceleration in respiration and basal
metabolism that ultimately lead to cell death. In contrast, bacteriostatic antibiotics suppress
cellular respiration and translation thus interfering with killing. It is plausible that the
altered responses of S. aureus and the tested gram-negative species to pA are caused by the
different effect of pA on metabolism in these microorganisms. We also investigated the
effect of PANDA disks (100 mm3) on membrane integrity of P. aeruginosa stained with
SYTO9 and propidium iodide at 0 h and 30 h by confocal imaging. Green-fluorescing
SYTO9 can penetrate intact and damaged bacterial membranes, whereas red propidium
iodide enters only cells with damaged cytoplasmic membranes and displaces SYTO9,
leading to red fluorescence when both dyes are present

206

. Prior to PANDA exposure (0

h), a majority of cells fluoresce green indicating intact membranes while after 30 h, a large
number of cells fluoresce red denoting damage of the cytoplasmic membranes (Fig. 5.4B
& 5.4C). To compliment the membrane integrity assay, transmission electron microscopy
(TEM) was also used to image P. aeruginosa after 0 and 30 h of incubation with a PANDA
disk. At 0 h, an intact membrane is clearly observed (Fig. 5.4D), however after 30 h, TEM
shows the complete destruction of the cell membrane with crumpled cell envelopes (Fig.
5.4E). These results show that PANDAs lead to a loss of respiratory activity and damage
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of cell membrane integrity, indicating that the pA released from PANDAs, can disrupt
membrane and damage other metabolic functions as previously reported in literature
208

207-

. Additionally, other labs have begun to elucidate the specific antimicrobial mechanism

of pA with evidence demonstrating up/down regulation of genes critical for cellular
survival

209

, and rapid shiff-base formation with amines potentially present in peptides,

proteins, and DNA/RNA 210.

Figure 5.4 Antibacterial activity of PANDAs. (A) ZOI of PANDA and control disks.
Plotted data points represent individual measurements. (B) Minimum inhibition assay of
different sized PANDA disks. (C) Time-dependent killing of pathogens by 100 mm3
PANDA disks. Data are representative of 2 independent experiments ± s.d.
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5.4.4 Antifungal activity of PANDAs.
5.4.4.1 Fungal inhibitory assays
To further probe the broad spectrum antimicrobial activity of PANDAs, we performed a
series of assays against the pathogenic fungus H. capsulatum. The invasive nature of H.
capsulatum coupled with its resistance to most azole-based antifungal treatments makes
the highly pathogenic H. capsulatum strain G217B, a model fungal system to assess
PANDA activity.211 As a preliminary experiment, a ZOI assay was performed with a 50
mm3 PANDA and control disk on yeast-phase H. capsulatum. Complete inhibition of
growth was observed with the PANDA treatment, whereas no measureable antifungal
activity was detected for the control disk (Fig. 5.5A). To determine the minimum PANDA
disk size required to inhibit H. capsulatum, PANDAs of various disk sizes (0-45 mm3)
were added to freshly passed cells, incubated, and every 24 h, optical density measurements
were recorded to assess the growth kinetics (Fig. 5.5B). As the size of the PANDA disk
increased, a reduction in H. capsulatum growth rate was observed, with 45 mm3 disks (32.8
µg mL-1 released in 24 h) completely inhibiting growth. In contrast, the control disk, as
expected, displayed a normal growth pattern with initial log phase (1-3 days) followed by
lag phase (3-7 days), which is consistent with healthy H. capsulatum growth. Interestingly,
the MIC for the fungus (32.8 µg mL-1) was significantly less than the MIC for the bacteria
(910 µg mL-1) indicating that the fungus is more sensitive to the PANDA disks than the
pathogenic bacteria tested.
5.4.4.2 Fungicidal activity of PANDAs
To examine the fungicidal activity of the PANDA disks, we utilized an Aqua live/dead cell
stain and flow cytometry. In brief, an exponential-growing culture of H. capsulatum was
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split in half where one half of the culture received a control disk and the other half received
a 50 mm3 PANDA disk. At 24 h and 48 h after PANDA addition, aliquots were taken and
subjected to staining, fixation (37% formaldehyde), confocal microscopy, and flow
cytometry to assess viability. Once complete gating was performed on the sample data, the
viability was determined as a percent of the survived cells. The Aqua fluorescent dye reacts
with amines yielding fluorescence, but is unable to penetrate living cells leading to weakly
fluorescent cells. However, compromised cellular membranes allow the dye to permeate
the cell, reacting with both cell-wall bound amines and intracellular amines, leading to
intense fluorescence. As shown in Figure 5.5C, at 48 h post addition the control disk cells
showed very little, if any fluorescence, indicating that the cell walls are functional and
intact. In contrast, treatment with the PANDA disks resulted in intense fluorescence from
all cells, indicating membrane destabilization and cell death (Fig. 5.5D). The difference in
fluorescence intensity is sufficient to quantify living from non-living cells using flow
cytometry (Fig. 5.5E). As shown in Figure 4.5F, roughly 25% of the H. capsulatum
population were viable within 24 h for the PANDA treatment, whereas virtually no change
in viability was observed for the control disk. After 48 h only 15% of PANDA treated H.
capsulatum cells remained viable whereas there was again no significant change in
viability in the control disk. We can conclude from this assay that the release of pA from
PANDAs results in potent membrane disruption and that the PANDA disk is not only
bactericidal but also fungicidal.
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Figure 5.5 Antifungal activity of PANDAs. (A) ZOI of PANDA and control disks. (B)
Minimum inhibition assay of different sized PANDA disks. Confocal microscopy images
of H. capsulatum challenged with control (C) and PANDA disks (D) after 48 h. (E) Flow
cytometry data of control and PANDA disks after 48 h incubation F) Time-dependent
killing of pathogens by PANDA. Data are representative of 3 independent experiments ±
s.d.
5.4.5 Cytotoxicity analysis
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Successful antimicrobial agents should possess both potency against pathogens as well as
low cytotoxicity to host cells. Clinically speaking, pathogens like H. capsulatum are
difficult to treat because they sequester themselves inside alveolar macrophages, one of the
most valuable immune cell needed to eradicate them. To evaluate PANDA cytotoxicity,
two cell lines, including RAW 264.7 murine macrophages and VERO epithelial cells
(isolated from kidney), were analyzed by directly exposing cells to multiple sizes of
PANDA disks [0.5 mm3 (18.2 µg mL-1), 1.0 mm3 (36.4 µg mL-1), and 1.5 mm3 (54.6 µg
mL-1)], 1.5 mm3 control disks, and a native control (blank). Cell viabilities were determined
using a MTT assay over a 24 h period. MTT is a colorimetric dye that assesses cellular
metabolic activity. In brief, live viable cells can reduce MTT to an insoluble formazan by
their native oxidase system, which is accompanied by a change in color to purple that can
be observed via spectrophotometry. As shown in Figure 5.6A, both cell lines showed no
significant decrease in viability (90-100 % viable compared to the native control) after
exposure to PANDA disks of various sizes (0.5-1.5 mm3), indicating minimal cytotoxicity
towards host cells. We also qualitatively investigated cell morphologies to ensure no
changes were observed after PANDA treatments. After 24 h, the cells treated with the
PANDA disk exhibited indistinguishable morphologies and confluency compared to the
control disk and native control. Macrophage cells displayed a dominant spherical
morphology with minimal pseudopodia (Figure 5.6B) whereas epithelial cells displayed a
spindle like morphology of closely aggregated cells (Figure 5.6C), both without any signs
of cytoplasmic vacuolation or granularity around the nucleus. Of significance, the low
cytotoxicity of PANDAs against macrophages at a concentration that is shown to eradicate
H. capsulatum holds great promise for clinical applications moving forward.
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Figure 5.6 Cytocompatability of PANDAs. (A) MTT assay of PANDAs incubated with
VERO kidney epithelial and RAW 264.7 macrophage cells. (B) Bright-field images of
macrophage and epithelial cells (C), incubated with either nothing (blank), a 1.5 mm3
control disk, or a 1.5 mm3 PANDA disk.
5.5 Conclusion
In summary, we have demonstrated a potent bio-based PANDA that has the versatility to
treat both prokaryotic and eukaryotic pathogens through the sustained release of pA over
time. The sustained release of pA allows many generations of the microbes to be exposed,
thus successfully clearing even slow growing pathogens such as H. capsulatum. Both
inhibitory and biocidal activity was measured against bacteria and fungi and found that the
fungi were significantly more susceptible to the PANDA treatment. Through a combination
of confocal microscopy and transmission electron microscopy, we showed PANDAs
primary mode of action is via membrane disruption. Additionally, we demonstrated that
PANDAs have minimal cytotoxicity towards both epithelial and macrophages which are
both relevant in immunosuppressed patient response. The PANDA network design coupled
with the potency of pA has the potential to be a streamline target to add to the arsenal of
defenses against a broad spectrum of pathogens and bares potential for future in vivo
experiments.

92

APPENDIX A – Supporting Information for Chapter III

Table A.1 General formulation of organic stock solutions for thiol-ene
photopolymerization in miniemulsion.
Organic Components Mass [g] Moles [mmol] wt. %
Diallyl phthalate

2.57

10.44

23.53

GDMP

2.00

8.39

18.32

PETMP

0.50

1.02

4.58

Carvacrol

2.90

19.31

26.56

p-methoxyphenol

0.05

0.40

0.46

Irgacure 184

0.10

0.49

0.92

Hexadecane

0.60

2.65

5.49

Thymol

2.20

14.65

20.15
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Figure A.1 1H NMR of starting materials and cured NPs.
1

H NMR of the starting materials: diallyl phthalate, PETMP, GDMP, carvacrol, and all three types of NPs after UV polymerization.

1

H spectrum confirmed the disappearance of both mercaptopriopionate (2.62-2.83 ppm) and alkene (5.07-5.45 ppm and 5.87-6.10

ppm) peaks after UV exposure.

Figure A.2 Raman spectra of TCNPs after ultrasonication (top, blue) and after exposure to
UV light (λ365 nm).
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Figure A.3 A) Surfactant concentration sweep of Hitenol BC-20 and B) Effect of weight
fraction of the organic monomer phase on particle size for TCNPs.

95

Figure A.4 Transmission electron microscopy of (A) c NPs, (B) CNPs, and (C) TCNPs.

Figure A.5 Absence of antimicrobial activity of B. subtilis by Hitenol BC-20 at 140 and
70 mM.
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Figure A.6 Antimicrobial activity of nanoparticles loaded with different ratios of
carvacrol and thymol (treatments I, II, and III). Controls included empty NPs (IV) and a
12:4 mixture of pure carvacrol and thymol (V).
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Figure A.7 Ramping conditions used for GC-MS separation of thymol and carvacrol
isomers.
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Separation of Essential Oil Isomers
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Figure A.8 Example separation of thymol and carvacol isomers eluting at 19.40 and
19.56 min respectively.
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Figure A.9 Calibration curves for thymol and carvacrol isomers.
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Table A.2 Nanoparticle size and concentration for different formulations.
Sample

Particle size (nm) [NP] (particles mL-1)

Control NPs (Butyl acetate)

183 ± 19

1.4 x 1013

CNPs (Carvacrol)

148 ± 24

2.7 x 1013

TCNPs (Thymol and Carvacrol) 147 ± 19

2.7 x 1013

Figure A.10 Additional data with controls: inhibition of B. subtilis ATCC 6633, E. coli
ATCC 25922, and S. aureus RN6390 with thiol-ene nanoparticles containing different
ratios of essential oils (shown in Table S5).
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Figure A.11 Additional data with controls: Inhibition of E. coli O157:H7 and B.
cenocepacia K56-2 with different types of NPs.
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Figure A.12 Absence of antimicrobial activity for different concentrations of carvacrol
and thymol/carvacrol in 70 mM Hitenol BC-20.
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Figure A.13 Additional TEM images of E. coli ATCC 25922 with TCNPs over time.
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Figure A.14 Additional TEM images of B. subtilis ATCC 6633 with TCNPs over time.
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APPENDIX B – Supporting Information for Chapter IV

Figure B.1 1H NMR of diallyl p-chlorobenzaldehyde acetal.
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Figure B.2 13C NMR of diallyl p-chlorobenzaldehyde acetal.

Figure B.3 Zones of inhibition for small molecule precursors within PANDA
formulation.
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Figure B.4 PANDAs exposed to HCl vapor led to complete bulk degradation in minutes
while ammonium hydroxide vapor led to retarded degradation with no flow observed
within 24 h.
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Nair, D. P.; Podgórski, M.; Chatani, S.; Gong, T.; Xi, W.; Fenoli, C. R.; Bowman,
C. N., The thiol-Michael addition click reaction: a powerful and widely used tool in
materials chemistry. Chem. Mater. 2013, 26 (1), 724-744.
48.
Azagarsamy, M. A.; Anseth, K. S., Bioorthogonal click chemistry: an
indispensable tool to create multifaceted cell culture scaffolds. ACS Publications: 2012.
109

49.
Liu, Z.; Lin, Q.; Sun, Y.; Liu, T.; Bao, C.; Li, F.; Zhu, L., Spatiotemporally
Controllable and Cytocompatible Approach Builds 3D Cell Culture Matrix by Photo‐
Uncaged‐Thiol Michael Addition Reaction. Advanced Materials 2014, 26 (23), 39123917.
50.
Lin-Gibson, S.; Jones, R. L.; Washburn, N. R.; Horkay, F., Structure− Property
Relationships of Photopolymerizable Poly (ethylene glycol) Dimethacrylate Hydrogels.
Macromolecules 2005, 38 (7), 2897-2902.
51.
Kloxin, A. M.; Kloxin, C. J.; Bowman, C. N.; Anseth, K. S., Mechanical
properties of cellularly responsive hydrogels and their experimental determination.
Advanced materials 2010, 22 (31), 3484-3494.
52.
Andorko, J. I.; Hess, K. L.; Pineault, K. G.; Jewell, C. M., Intrinsic
immunogenicity of rapidly-degradable polymers evolves during degradation. Acta
biomaterialia 2016, 32, 24-34.
53.
Tesar, B.; Jiang, D.; Liang, J.; Palmer, S.; Noble, P.; Goldstein, D., The role of
hyaluronan degradation products as innate alloimmune agonists. American Journal of
Transplantation 2006, 6 (11), 2622-2635.
54.
Termeer, C. C.; Hennies, J.; Voith, U.; Ahrens, T.; Weiss, J. M.; Prehm, P.;
Simon, J. C., Oligosaccharides of hyaluronan are potent activators of dendritic cells. The
Journal of Immunology 2000, 165 (4), 1863-1870.
55.
Termeer, C.; Benedix, F.; Sleeman, J.; Fieber, C.; Voith, U.; Ahrens, T.; Miyake,
K.; Freudenberg, M.; Galanos, C.; Simon, J. C., Oligosaccharides of Hyaluronan activate
dendritic cells via toll-like receptor 4. Journal of Experimental Medicine 2002, 195 (1),
99-111.
56.
Scheibner, K. A.; Lutz, M. A.; Boodoo, S.; Fenton, M. J.; Powell, J. D.; Horton,
M. R., Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. The
Journal of Immunology 2006, 177 (2), 1272-1281.
57.
Carioscia, J. A.; Lu, H.; Stanbury, J. W.; Bowman, C. N., Thiol-ene oligomers as
dental restorative materials. Dental Materials 2005, 21 (12), 1137-1143.
58.
Kim, S.; Linker, O.; Garth, K.; Carter, K. R., Degradation kinetics of acidsensitive hydrogels. Polymer Degradation and Stability 2015, 121, 303-310.
59.
Chen, N.; Dempere, L. A.; Tong, Z., Synthesis of pH-Responsive Lignin-Based
Nanocapsules for Controlled Release of Hydrophobic Molecules. ACS Sustainable
Chemistry & Engineering 2016, 4 (10), 5204-5211.
60.
Amato, D. N.; Amato, D. V.; Mavrodi, O. V.; Braasch, D. A.; Walley, S. E.;
Douglas, J. R.; Mavrodi, D. V.; Patton, D. L., Destruction of Opportunistic Pathogens via
Polymer Nanoparticle-Mediated Release of Plant-Based Antimicrobial Payloads.
Advanced Healthcare Materials 2016, 5 (9), 1094-1103.
61.
de Meneses, A. C.; dos Santos, P. C. M.; Machado, T. O.; Sayer, C.; de Oliveira,
D.; de Araújo, P. H. H., Poly (thioether-ester) nanoparticles entrapping clove oil for
antioxidant activity improvement. Journal of Polymer Research 2017, 24 (11), 202.
62.
Machado, T. O.; Cardoso, P. B.; Feuser, P. E.; Sayer, C.; Araújo, P. H., Thiol-ene
miniemulsion polymerization of a biobased monomer for biomedical applications.
Colloids and Surfaces B: Biointerfaces 2017, 159, 509-517.
63.
Durham, O. Z.; Poetz, K. L.; Shipp, D. A., Polyanhydride Nanoparticles: Thiol–
Ene ‘Click’Polymerizations Provide Functionalized and Cross-Linkable Nanoparticles
110

with Tuneable Degradation Times. Australian Journal of Chemistry 2017, 70 (6), 735742.
64.
Poetz, K. L.; Mohammed, H. S.; Shipp, D. A., Surface Eroding, Semicrystalline
Polyanhydrides via Thiol–Ene “Click” Photopolymerization. Biomacromolecules 2015,
16 (5), 1650-1659.
65.
Wang, J.; Wang, X.; Yan, G.; Fu, S.; Tang, R., pH-sensitive nanogels with ortho
ester linkages prepared via thiol-ene click chemistry for efficient intracellular drug
release. Journal of colloid and interface science 2017, 508, 282-290.
66.
Chen, C.-K.; Wang, Q.; Jones, C. H.; Yu, Y.; Zhang, H.; Law, W.-C.; Lai, C. K.;
Zeng, Q.; Prasad, P. N.; Pfeifer, B. A., Synthesis of pH-responsive chitosan nanocapsules
for the controlled delivery of doxorubicin. Langmuir 2014, 30 (14), 4111-4119.
67.
Wang, Y.; Luo, Q.; Zhu, W.; Li, X.; Shen, Z., Reduction/pH dual-responsive
nano-prodrug micelles for controlled drug delivery. Polymer Chemistry 2016, 7 (15),
2665-2673.
68.
Amato, D. N.; Amato, D. V.; Mavrodi, O. V.; Martin, W. B.; Swilley, S. N.;
Parsons, K. H.; Mavrodi, D. V.; Patton, D. L., Pro-Antimicrobial Networks via
Degradable Acetals (PANDAs) Using Thiol–Ene Photopolymerization. ACS Macro
Letters 2017, 6 (2), 171-175.
69.
Amato, D. V.; Amato, D. N.; Blancett, L.; Mavrodi, O. V.; Martin, W. B.;
Swilley, S. N.; Sandoz, M. J.; Shearer, G.; Mavrodi, D. V.; Patton, D. L., A bio-based
pro-antimicrobial polymer network via degradable acetal linkages. Acta biomaterialia
2017.
70.
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